

Vision Awards

Showcase your achievements at the Vision Awards 2012. Enter for free today

► napcannual.co.uk/enter-awards



Pulse Learning

Update yourself on the latest NICE alcohol misuse guidance in our case-based CPD

► pulse-learning.co.uk



PULSE

pulsetoday.co.uk

30.05.12

Issue 20 | Volume 72

BriefingMedia

At the heart of general practice since 1960

GPs to be forced to use Choose and Book

DH says GPs who refuse must adopt 'labour-intensive' alternatives or face sanctions

By Jaimie Kaffash

GPs will be forced to refer patients through Choose and Book or call around multiple hospitals to check appointment availability in person, under radical Government plans to extend choice of NHS services.

Practices will be expected to adopt 'labour-intensive' alternatives if they refuse to use the controversial electronic referral service, with the Department of Health consulting on sanctions for those who refuse, in a move condemned by the GPC as 'highly inappropriate'. The DH is even looking at giving patients direct access to Choose and Book through NHS Choices so they can book their own appointments.

The proposals are part of a wide-ranging DH initiative to force GPs to engage with the choice agenda, outlined in the *Liberating the NHS: No decision about me, without me* consultation published last week.

GP use of Choose and Book will be published so patients can 'exert pressure' on practices to provide choice, while GPs will also be asked to offer patients a choice of diagnostic providers, initially for MRI scans and non-obstetric ultrasound.

EDITORIAL ►

A tangle of logical contradictions 12

The Government will also begin routinely using alternative providers to treat patients who miss the 18-week target, with pilots this year focusing on orthopaedic services and full rollout from next April.

The Government's national target is for 90% of referrals to be made through Choose and Book, but in January Pulse revealed

the DH had launched an investigation after use fell to just 50%, from a high of 57%.

The fall came after many PCFs removed LES incentives for GPs' use of the system.

In its new strategy, the DH

said a 'cultural change' was needed on choice and that it was determined to ramp up Choose and Book use.

'We are working to maximise use of Choose and Book so that more referrals are made through

it,' the DH said. 'Where Choose and Book is not being used, formal requirements to support greater choice for patients will have to be met by alternative, potentially labour-intensive, methods.'

The DH told Pulse it would be up to GPs to find alternative ways of providing choice, but said this could include phoning round providers to check their services and sending hard-copy referral letters.

Sanctions for GPs found not to offer choice were being consulted on, a spokesperson said: 'GP practices that don't use Choose and Book will need to make alternative arrangements to ensure people have more

choice in their care. Alternatives may well create more burdens on doctors.'

GPs responded angrily, with GPC negotiator Dr Chaand Nag-paul claiming it was 'highly erroneous' to blame GPs for not using Choose and Book: 'The main reason they don't is it is too slow and interferes with consultations. It is inappropriate for GPs to be pursuing any "labour-intensive" approach to a choice political agenda when the priority must be time with patients.'

Dr Andrew Minnagh, chair of Sefton LMC and a GP in Waterloo, Merseyside, said: 'If the software actually worked, it would be used.'

feedback@pulsetoday.co.uk

Plans to extend choice



Choose and Book
GPs must use it or make other arrangements



Diagnostics
Patients allowed to choose provider



Private treatment
Offered if NHS cannot meet waiting times

BALLOTS WERE ON GPs' MINDS AT THE LMC CONFERENCE



Industrial action ballot

GPs will learn the result of the historic ballot on industrial action over pensions this week. Check Pulse's website for the result and the BMA's decision on what action to take. ► pulsetoday.co.uk/news

LMC Conference

For full coverage of LMC Conference 2012, including votes on pensions, turn to pages 4-5

News

2 Report predicts 120,000 new patients to register in City under boundary pilot

4 LMCs vote for commissioning boycott over pensions

Views

14 Peverley Yes, it might be lung cancer

14 Margaret McCartney Wake up to the perils of awareness


15 Opinion Pharmacist interventions won't solve script errors

PulsePlus

18-23

Neurology

Our monthly CPD section updates you in a clinical area, giving you the chance to earn credits for appraisal and revalidation



18 Key questions Multiple sclerosis
20 Update on stroke management
21 Urgent neurological problems
22 Five misconceptions in neurology
23 Ten top tips Parkinson's

Business & Commissioning

24 Nine ways to avoid costly data breaches

25 Using volunteers to deliver healthcare

CPD in this issue: 3 hours

Earn CPD for our PulsePlus on neurology

Seminars

Prepare for the future with Practice Finance Skills
pulsetoday.co.uk/seminars

A survey of 2,519 workers included in the report - published this month - found 33% would prefer to register close to work, and 82% backed dual registration. If all patients who wished to register near to work did so, there would be an extra 130,000 registrations, requiring 14 practices to be opened to add to the one currently in the Square Mile, the report warned. It estimated 50 new GPs and 50 new practice nurses would need

CCGs to link up



'CCGs should not use this as a way to make short-term savings'
Dr Richard Vautrey

Ministers to block GPs from

But the Department of



WWW.DEPOMEDRONE.CO.UK

DEPO-MEDRONE®

Methylprednisolone BP 4%

50+ years and still going strong



Working together for a healthier world

[illegible][illegible][illegible]

Adverse events should be reported.
Reporting forms and instructions can be found at www.fda.gov/oc/yellowcard.
Adverse events should also be reported to:
Drug Toxicology Information ex. 01368 CIGCET



Dr Jacqueline Applebee: pilots treat healthcare as a commodity

to be recruited, and additional adult counselling services and extended-hours capacity would be required.

Initially resource use might be even higher, as new patients tend to see their healthcare providers twice as frequently as patients who have been registered for a while, the report said.

GPs working at the Neuman Practice in the City of London 'recognised the potential benefits of City workers being able to register with a GP practice closer to work', but were concerned they did not have the resources to cope, the report added. NHS City and Hackney is part of the current practice boundary pilot scheme along with NHS Tower Hamlets - where about 100,000 people work at Canary Wharf -

Westminster, Nottingham, Salford and Manchester.

No practices have signed up from either City and Hackney or Tower Hamlets, even though the scheme was due to start in April, and few practices have signed up elsewhere.

Dr Sella Shanmugadasan, chair of Tower Hamlets LMC, said: 'They are not offering any additional resources during the pilot period to meet extra demands. We are already struggling to meet our needs.'

Last week's LMC conference voted in favour of abolishing the practice boundary pilots. Dr Jacqueline Applebee, a GP in Tower Hamlets, said the pilot 'treated healthcare as a commodity rather than a precious resource'. feedback@pulsetoday.co.uk

with pharma

ments' with CCGs, which would only pay full price for drugs if targets on clinical outcomes were met, and the new document aims to expand on this. It lists a number of joint projects between drug companies and the NHS, including review of patients with COPD, a GP-led angina clinic and provision of care managers for patients with CVD.

A spokesperson for the ABPI said it wanted to ensure collaborations like these could continue after CCGs were authorised: 'We would encourage CCGs to engage with local pharmaceutical representatives and highlight areas where patients could benefit from combining the skills and resources of the NHS and pharmaceutical industry.'

A DH spokesperson said: 'We

have worked with the ABPI for a number of years to promote joint working between the NHS and industry. It is up to each project to establish governance arrangements.'

But Dr Richard Vautrey, GPC deputy chair, said there was a clear conflict of interest when involving drug companies in planning care: '[CCGs] should not use this as a way to make short-term savings, as the long-term adverse effects might be greater.'

Dr Des Spence, a GP in Glasgow whose BMJ column is often critical of the pharmaceutical industry, said: 'If there is under-diagnosis it should be judged by someone who has no vested interest. CCGs are naive if they can't see this is bad idea.'

▶ @nigelpratties

offering private services

Health said it would not accept the changes if brought forward, with the GPC also appearing reluctant to act on the vote.

The motion, proposed by Dr Nimish Shah, a GP in Bridgend and member of Morgannwg LMC, said: 'Conference urges GPC to negotiate a change to the GMS contract that would allow patients to receive treat-

ment not funded by the NHS from their own GP on a private basis.

He added: 'The perceived conflict of interest is nonsense.'

Dr Chand Nagpaul, GPC negotiator, said: 'This issue raises a Pandora's box of questions. It is fiendishly complex.'

▶ Full LMC coverage, page 4

RCGP tries to ban half its candidates for president

Three of the six leading GPs standing in the RCGP presidential election were originally barred from standing and were only reinstated after legal advice, Pulse can reveal.

Dr Una Coales, an RCGP Council member and one of the six candidates standing, claimed on her blog last week that the college's nominations committee banned half of the candidates now in the race from standing last month, with one candidate told they were 'not fit and proper' for the role.

The RCGP would not comment on the reasons for the bans, or confirm the names of the three candidates concerned,

whom Pulse has decided not to identify.

This year's tightly contested race includes former GPC chair Dr John Chisholm, Dr Coales, North West Deanery post-graduate dean Professor Jacky Hayden, Bristol GP Dr Terry Kempe, Department of Health QIPP lead Sir John Oldham and former RCGP chair Professor Mike Pringle.

Dr Coales said the three candidates were initially told they would not be put forward for the ballot in an email on 16 April.

But following an appeal from two of the three candidates, RCGP chief executive Neil Hunt decided to reinstate all three.

Advertisement Feature

First choice for cost-effective CMA management



Dr Joanne Walsh explains how using Nutramigen as the first-line formula for cow's milk allergy is supported by expert guidelines,¹ and can reduce costs by up to £1,300 per patient in the first year of management in primary care.²

Cow's milk allergy (CMA) affects 2-7.5% of infants,³ making it a major paediatric health problem in the UK. Recent NICE guidelines on food allergy in children provide a valuable guide for diagnosis in primary care.⁴ To diagnose and manage CMA in formula-fed infants, a hypoallergenic formula is needed. Expert bodies have established the following guidance for choosing an appropriate formula:

- Extensively hydrolysed formula (eHF), such as Nutramigen, is effective in >90% of infants with CMA and should be used as the first-line hypoallergenic formula in the majority of cases¹
- Amino acid-based formula (AAF), such as Nutramigen AA and Neocate[®] LCP, should be reserved for severe CMA, multiple allergies, or when eHF is ineffective^{1,3}
- Soya formula is not recommended in infants under 6 months,⁵ and a substantial proportion of infants with CMA are also allergic to soya⁶

With the pressing need to review prescribing costs, GPs are looking for ways to save money while optimising quality of care for patients. A new study has demonstrated that by using Nutramigen first-line, GPs can align practice to expert recommendations while reducing costs by up to 41% (£1,300) per CMA patient in the first year of management.² Nutramigen is the leading hypoallergenic formula in the UK, supported by over 70 years of experience in managing CMA and over 70 clinical studies.

Using Nutramigen first-line can reduce costs by 41% per CMA patient in the first year²

Taylor et al. compared healthcare resource use and associated costs in infants with CMA who presented with similar symptoms.² In all, 150 infants were initially prescribed Nutramigen (eHF), in line with the expert guidelines, and 145 were initially prescribed Neocate (AAF).²



First for cow's milk allergy

Study results

- **No significant difference in clinical outcomes**
 - Nutramigen (eHF) is as effective as Neocate (AAF) in newly diagnosed infants with CMA²
 - Both groups achieved symptom resolution by 5 weeks²
- **Nutramigen is cost effective vs Neocate**
 - Prescribing Nutramigen first-line reduced NHS costs by £1,300 per patient over the first 12 months of management, compared to Neocate²

Reduce NHS costs by £1,300 per CMA patient in the first year of management with Nutramigen (2008/9 prices)²

	Total NHS costs in first 12 months	
	Nutramigen	Neocate
Per infant	£1,853	£3,161
For 12 patients	£22,236	£37,932

Current prices per 400g tin: Nutramigen LIPIL – £10.11; Neocate LCP – £26.22 (MIMS, April 2012)

Nutramigen has proven efficacy for the management of CMA. In addition, the new comparative study demonstrates that Nutramigen is cost effective compared to Neocate in this patient group.² Using Nutramigen as the first-line formula for the majority of infants with CMA matches expert guidelines,¹ reduces costs by 41% in the first year of management and can potentially save money when compared to using Neocate.²

Dr Joanne Walsh BSc MBChB DFFP MSc is a Norwich GP with an interest in allergy.

First line for CMA



Up to 6 months From 6 months

Mead Johnson Carline
+44 (0)1895 230575

www.nutramigen.co.uk

IMPORTANT NOTICE: Breastfeeding is best for babies. The decision to discontinue breastfeeding may be difficult in some cases and the introduction of partial bottle-feeding may reduce breast milk supply. The greatest benefits of breastfeeding should be considered before bottle-feeding is initiated. Failure to follow preparation instructions carefully may be harmful to a baby's health. Parents should always be advised by an independent healthcare professional regarding infant feeding. Products of Mead Johnson must be used under medical supervision. [®] Trademark of Mead Johnson & Company, LLC. © 2012 Mead Johnson & Company, LLC. All rights reserved.

References: 1. Vandenplas Y et al. Arch Dis Child 2007;92:462-8. 2. Taylor RH et al. Pediatr Allergy Immunol 2011;22:249-54. 3. Du Toit G et al. Arch Dis Child Educ Pract Ed 2010;95:134-44. 4. National Institute for Health and Clinical Excellence. CG136: Food allergy in children and young people. 2011. 5. British Dietetic Association. Paediatric Group. Formulae contain more than 100 different proteins. 2010. 6. Agostoni C et al. J Pediatr Gastroenterol Nutr 2008;47:352-61.

PENSIONS

LMCs back reforms
boycott over pensions

Narrow vote supports extension of pension action to hit commissioning

By Gareth Iacobucci

Say No to
30%

The BMA is to consider including a boycott of commissioning as part of future industrial action over the Government's pension reforms, after a key vote at the annual LMC conference in Liverpool.

In a passionate debate, LMCs overwhelmingly supported industrial action as a means of registering the profession's anger at ministers' raid on GPs' pensions.

But in a narrow 48% to 37% vote, LMC representatives also backed a motion recommending 'the disengagement of GPs from clinical commissioning be included in any industrial action'.

The vote comes as a boost for Pulse's *Say No to 30%* campaign, a key strand of which calls on the BMA to follow up on its proposed 'day of action' by balloting on a boycott of non-clinical work.

GPC leaders said the BMA would take account of the vote if planning any potential industrial action, but said the issue was complicated by the fact that the ballot taking place was UK-wide, while the possibility of withdrawing from commissioning was limited to England.

Dr Terry John, chair of Waltham Forest LMC, who proposed the motion, said: 'It is important for this conference to send a message. We need to take a stand.'

Dr Anthony O'Brien, a member of Devon LMC, said: 'Disengaging temporarily from clinical commissioning would have a dramatic effect. We have a massively powerful tool. We should use it.'

Dr Fay Wilson, BMA Council member and a member of Birmingham LMC, also backed industrial action, and issued a rallying cry to LMCs: 'If we are not prepared to stand up and be counted, they'll be back next year. We are being blackmailed because of our devotion to patients. Grit your teeth and walk the walk.'

The boycott vote was carried despite the GPC warning that withdrawing from commissioning would work against the profession.

GPC negotiator Dr David Bailey said withdrawal could 'leave the door open for enthusiasts - the 5% of our profession who think clinical commissioning is a way of controlling the rest of us'.

Following the vote, GPC negotiator Dr Chaand Nagpaul told

Pulse the BMA would consider the vote when planning any future industrial action.

But he cautioned: 'It's a UK-wide ballot, and GPs withdrawing from commissioning is an English issue.'

In a separate motion, GPs called on the Government to reconsider its controversial pen-

sion reforms and return to negotiations with the profession, and warned there was 'a danger of workers of all ages leaving the NHS' because of the changes.

@garethiacobucci

JOIN OUR CAMPAIGN
Sign up at
pulsetoday.co.uk/saynoto30



LMC leaders met in Liverpool for the first time

NASONEX 50 micrograms/actuation Nasal Spray, Suspension (Phenylethyl alcohol-free formulation)

PRESCRIBING INFORMATION

Refer to Summary of Product Characteristics (SPC) before prescribing

Please refer to the full SPC text before prescribing this product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events with this product should also be reported to MSD Drug Safety Department on +44 (0)1767 363773

Presentations: Nasal spray suspension containing mometasone furoate (as monohydrate) 50 micrograms/actuation, a synthetic topical corticosteroid. **Indications:** Adults and children aged 12 and over: treatment of nasal polyps. Adults and children over the age of 12 years: for the treatment of the symptoms of seasonal allergic rhinitis or perennial allergic rhinitis. **Children 6 to 11 years of age:** For the treatment of the symptoms of seasonal allergic rhinitis or perennial allergic rhinitis. In patients who have history of moderate to severe symptoms of seasonal allergic rhinitis, prophylactic treatment with Nasonex may be initiated up to four weeks prior to the anticipated start of the pollen season. **Usage:** Nasal Polyps: Adults and children aged 12 and over: The usual recommended starting dose for polyps is two actuations (50 micrograms/actuation) in each nostril once daily (total daily dose of 200 micrograms). If after 5 to 6 weeks symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays in each nostril before daily (total daily dose of 400 micrograms). The dose should be reduced following control of symptoms. If no improvement in symptoms is seen after 5 to 6 weeks of twice daily administration, alternative therapies should be considered. **Efficacy and safety studies of Nasonex Nasal Spray for the treatment of nasal polyps:** Four months in duration. **General or Perennial Allergic Rhinitis:** Adults and children over the age of 12 years: Two sprays (50 micrograms/spray) in each nostril once daily (total dose 200 micrograms). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose 100 micrograms) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of four sprays in each nostril (total dose 400 micrograms). Dose reduction is recommended following control of symptoms. **Children 6 to 11 years of age:** One spray (50 micrograms/spray) in each nostril once daily (total dose 100 micrograms). Clinically significant onset of action occurs in some patients within 12 hours after the first dose. Full benefit of treatment may not be achieved in the first 48 hours. Regular use is recommended to achieve full therapeutic benefit. **Contraindications:** Hypersensitivity to any of the ingredients. Do not use in the presence of untreated localised infection involving the nasal mucosa. Patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred. **Precautions and Warnings:** Use with caution if at all in patients with active or quiescent tuberculosis infections of the respiratory tract, or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex. There was no evidence of absorption of the nasal mucosa following 12 months of treatment. Patients using Nasonex over several months or longer should be monitored periodically for changes in the nasal mucosa. If localised fungal infection of the nose or pharynx develops, discontinuation of Nasonex therapy or appropriate treatment may be required. The absence of nasopharyngeal infection may be an indication for discontinuing Nasonex. The concomitant use of additional therapy may provide additional relief particularly of ocular symptoms. There is no evidence of PPA risk suppression following prolonged treatment with Nasonex. Patients who are considered for long-term administration of systemically active corticosteroids to Nasonex require careful attention. The safety and efficacy of Nasonex has not been studied for use in the treatment of initial polyps, polyps associated with cystic fibrosis, or polyps that completely obstruct the nasal cavity. Unilateral polyps that are unilateral or invasive in appearance, especially if bleeding or bleeding associated with the polyp. Patients who are potentially immunosuppressed should be warned of the risk of exposure to certain infections. Very rarely, nasal septum perforation or increased intracranial pressure have been reported following the use of intranasal corticosteroids. Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed over long periods. These may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Nasonex should only be used in pregnant women, nursing mothers or women of child-bearing age if the potential benefit justifies the potential risk to the mother, foetus or infant. It is recommended that the height of children requiring prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid, if possible, to the lowest dose at which effective control of symptoms is maintained. In addition, consideration should be given to referring patient to a paediatric specialist. **Safety and efficacy of Nasonex Nasal Spray for the treatment of nasal polyps in children and adolescents under 12 years of age:** has not been studied. Treats and with higher dose recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. In a placebo-controlled clinical trial in which patients with nasal polyps were administered Nasonex 100 micrograms daily for one year, no reduction in growth velocity was observed. **Interactions:** A clinical interaction study was conducted with isotretinoin. No interactions were observed. **Side Effects:** Adverse effects commonly reported in clinical trials in adults and adolescent patients include headache, epistaxis, pharyngitis, nasal burning, nasal irritation and nasal ulceration. Other less common and rarely reported side effects are listed in the SPC. **Package Quantities:** 100 per bottle, supplied with a metered-dose manual spray pump actuator which delivers 50 micrograms per actuation. MS Price: £7.85. **Legal Category:** Prescription Only Medicine. **Marketing Authorisation Number:** PL 00025/09/07. **Marketing Authorisation Holder:** Merck Sharp & Dohme Limited, Bedford Road, Welwyn Garden City, Herts SG13 7PL, UK. **Date of Revision of Text:** January 2012

© Merck Sharp & Dohme Limited 2012. All rights reserved.
MSD is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck and Co. Inc., Whitehouse Station, NJ, USA.

Reference: 1. MS Health/PAVER PEMA, November 2012 - October 2011

CD-13 (HSP)-1007562-0004

Date of preparation: February 2012

LMC conference videos



GPC chair
Dr Laurence
Buckman's
keynote speech



Dr Fay Wilson on
pensions: 'It's time
to stand up and be
counted'



Dr John Crompton
on whether GPs
could strike

pulsetoday.co.uk/videos

KEYNOTE SPEECH

'Tough times' for GPs

GPs' efforts to navigate an NHS heading towards 'financial and operational meltdown' are being hampered by 'regulation, bullying micromanagement and dissipated effort', GPC chair Dr Laurence Buckman has warned.

In a defiant keynote speech to representatives - his fifth as GPC chair - Dr Buckman took aim at a raft of Government policies, including pension reforms, revalidation and the removal of practice boundaries, and warned GPs' working lives were becoming unsustainable.

He said the extension of GP training and the 100th anniversary of the GPC had represented

some 'rays of light' in the past year, but said GPs were operating in 'tough, uncertain and not very happy times'.

'All of us can see that workloads are rising back to 1999 levels, and most of us are back to 12-hour days,' he said.

'If we are continually ignored, we are going to be forced to walk away as our practices, our health and our solvency fail. This is not a threat - merely recognising reality.'

Dr Buckman also warned CCGs were developing without the involvement of many grassroots GPs, and said they must be made to work with LMCs.

REVALIDATION

GMC under fire over revalidation plans

By Gareth Iacobucci

LMCs have heaped pressure on the GMC by voting unanimously that revalidation must not go ahead without adequate arrangements for remediation that fully cover all types of GP.

Representatives at the annual LMC conference also poured scorn on the GMC for its 'total lack of leadership' on the policy, as GPs made their feelings known ahead of its planned introduction next year.

The motion insisted revalidation 'must not go ahead without proper arrangements for

remediation, which are no more burdensome for GPs than for other doctors', and 'proper arrangements for all types of GPs, including sessional and prison GPs'.

It also called for any process to be 'simple, sensible and non-threatening', and 'not result in any increase in GMC fees for GPs'.

The vote came after Professor Malcolm Lewis, a GMC council member and a GP in Swansea, told the conference disagreements over remediation 'shouldn't be a delaying factor' for revalidation, as the majority

of GPs would not need it.

GPs also expressed their anger at the GMC's policy of offering private medical insurance to its staff, as first revealed by Pulse back in January.

Dr Andrew Green, chair of East Yorkshire LMC, who proposed the revalidation motion, said: 'There has been a total lack of leadership by the GMC, and shocking complacency shown in front of us to say remediation and revalidation are not the same thing.'

'Revalidation needs to work for all of us. If it isn't fair for all doctors, it isn't fit for purpose.'

The vote came after the GPC had encouraged GPs to back the motion, with GPC negotiator Dr Dean Marshall saying it was 'completely unacceptable' to push ahead when arrangements were not in place for all doctors, including sessional GPs.

Dr Marshall said: 'The GMC are shirking their responsibility to sort this out. They are clearly not getting the message. It was an incredibly unfortunate comment that it will only apply to a few doctors.'

'The GMC has made a complete and utter hash of this.'

@garethiacobucci



Professor Malcolm Lewis (right) is introduced to the LMC bear pit

IN BRIEF

CQC registration

GPs demanded that practices should not incur any expense from CQC registration, unanimously backing a motion condemning current plans as 'a bridge too far'.

NHS 111

LMCs voted in favour of a motion warning the Government's rushed imposition of NHS 111 would compromise patient safety,

and endanger existing GP out-of-hours services.

Work assessments

Representatives also backed a call for the work capability assessments run by private firm Atos to 'end with immediate effect', and be replaced with 'a rigorous and safe system that does not cause avoidable harm to some of the weakest and most vulnerable in society'.

HEALTH ACT

BMA faces down LMCs

BMA leaders have faced down a rebellion by LMCs over their policy of 'constructive engagement' with the NHS reforms.

A motion proposed by Dr Paul Hobday, a GP in Maidstone, Kent, asked LMCs to reprimand the BMA leadership for 'taking so long to wake up to the malignant effect of the Health and Social Care Act'. But representatives rejected the motion after a heated debate, in which BMA chair Dr Hamish Meldrum and GPC chair Dr Laurence Buckman defended their stance.

Dr Hobday questioned why

the BMA had refused to ballot members on possible industrial action over the health act, and criticised its failure to lead an effective public campaign.

Dr David Wrigley, a GPC member and a GP in Carnforth, Lancashire, said he backed the motion. 'This bill wasn't a curate's egg - it was a very badly smelling egg,' he said, quoting Dr Meldrum's original description of the reform package.

But Dr Ivor Camphor, medical secretary of Mid Mersey LMC, dismissed the motion as 'in-fighting and quarrelling'.

ANALYSIS

A sense of moderation



Gareth Iacobucci
Chief reporter

The annual LMC conference is probably the most

reliable barometer of grassroots GP opinion there is. So with the profession facing unprecedented challenges from all sides, what did this year's summit tell us?

Pensions is by far the most pressing issue on GPs' minds, with leaders fizzing with anger over the Government's raid on their retirement pots. In fact, the almost placid consensus on many other issues suggested GPs are saving most of their fight for the proposed industrial action.

That's not to say there weren't other flashpoints - anger at the NHS reforms still burns, although the debate

has moved from principle to concerns over implementation. GPC chair Dr Laurence Buckman warned of CCGs shutting out the rank and file.

The GMC took a battering over its handling of revalidation, as did the Government for its hurried rollout of NHS 111, and hospitals for the seemingly never-ending amount of unresourced work being dumped on primary care.

But despite all this, a sense of reasoned moderation hung in the air, as the BMA escaped censure for its handling of the NHS reforms, and calls for Andrew Lansley and David Cameron to resign were dismissed as 'gesture politics'.

With the ballot on industrial action over pensions closing this week, GPs are perhaps keeping their eyes on the bigger prize.

confidence



Alcohol-Free
Nasonex
mometasone furoate 50mcg per spray

The No.1 used INS product in the UK*

Benefits remain if drugs are stopped after three years

OSTEOPOROSIS

Bisphosphonate
benefits fade

By David Swan

GPs can discontinue bisphosphonate treatment in postmenopausal women after three to five years without substantially increasing their risk of a subsequent fracture, say experts after a major review of recent evidence into the drugs.

The review by the US Food and Drug Administration found fracture rates were 'remarkably similar' in postmenopausal women taking bisphosphonates for over nine years, and those who switched to placebo after three to five years of continuous bisphosphonate therapy.

The advice comes after a major study linked bisphosphonate treatment with an increased risk of atypical femoral fractures, compounding concerns over long-term use of the drugs to prevent osteoporosis.

The FDA pooled data from three trials involving 2,496 women who took bisphosphonates for three to five years. Some of the women continued taking the treatments for six or more years, while others switched to placebo.

Those who continued treatment had mean fracture rates of 9.3-10.6% while those switched to placebo had rates of 8.0-8.8%.

The analysis concluded: 'Statistical limitations preclude inferring any meaningful association between long-term treatment and increased risk of fracture.'

In an editorial discussing the FDA's analysis, experts from the University of California recommended that GPs consider discontinuing bisphosphonate treatment after three to five years in the light of 'safety concerns' over atypical fractures with long-term use: 'The available data do suggest that bisphosphonates may be safely discontinued in some patients without compromising therapeutic gains, but no adequate clinical trials have yet delineated how long the drugs' benefits are maintained after cessation.'

The advice comes as a new case-control study looked at 477 patients hospitalised with a subtrochanteric or femoral fracture.

They found 82% of patients treated for atypical fractures had been treated with bisphosphonates, compared with just 6.4% of patients with classic fractures. There was also an increased risk of atypical fracture in those patients who had a longer duration of bisphosphonate treatment.

Dr Pam Brown, a GP in Swansea and clinical assistant in osteoporosis, said the FDA recommendations should encourage GPs to review all bisphosphonate patients after three years and discontinue alendronate or zoledronate 'in those without previous vertebral fractures'.

N Eng J Med 2012, online 9 May

Arch Intern Med 2012, online 21 May
david.swan@pulsetoday.co.uk

Key findings

Group	Mean fracture rates over six years (%)
Women remaining on bisphosphonates	9.3-10.6
Women switched to placebo	8.0-8.8

Source: *N Eng J Med* 2012, online 9 May



Stopping bisphosphonates does not increase fracture risk

Online CPD
Clinical
casebook:
osteoporosis



OBSTETRICS

Diets in pregnancy 'improve outcomes'



A change of diet can significantly reduce weight gain in pregnancy and improve outcomes for newborn babies, according to UK researchers.

Their meta-analysis of 44 randomised trials involving 7,300 women found dietary interventions reduced weight gain during pregnancy by 3.84kg, compared with those who underwent no intervention.

A physical activity intervention resulted in a mean reduction in weight gain of 0.72kg, compared with those not undergoing the intervention, and combining the two approaches reduced weight gain by 1.06kg.

Dietary interventions were also associated with a 70% reduction in risk of gestational hypertension - compared with an 8% increase with a mixed intervention - and a reduction

of 61% in the risk of gestational diabetes.

Study leader Dr Shakila Thangaratinam, consultant in obstetrics and maternal medicine at Barts and the London School of Medicine and Dentistry, said: 'With the clear benefit in gestational weight gain with dietary interventions in pregnancy, there is a potential for this strategy to be cost-effective compared with other methods.'

BMJ 2012, online 17 May

Relax,
Urgency
controlled

ABBREVIATED PRESCRIBING INFORMATION

Presentation: Vesicare® film-coated tablets containing 5 mg or 10 mg solifenacin succinate. **Indication:** Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. **Dosage:** Adults: Recommended dose: 5 mg once daily. If needed, the dose may be increased to 10 mg once daily. **Children and adolescents:** Should not be used. **Contraindications:** Urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and in patients at risk for these conditions. Patients hypersensitive to the active substance or to any of the excipients, or undergoing haemodialysis, or with severe hepatic impairment, or with severe renal or moderate hepatic impairment and on treatment with a potent CYP3A4 inhibitor. **Warnings and Precautions:** No clinical data are available from women who became pregnant while taking solifenacin. Caution should be exercised when prescribing to pregnant women. The use of Vesicare® should be avoided during breast-feeding. Assess other causes of frequent urination

before prescribing. Use with caution in patients with clinically significant bladder outflow obstruction at risk of urinary retention, gastrointestinal obstructive disorders, risk of decreased gastrointestinal motility, autonomic neuropathy, severe renal or moderate hepatic impairment (doses not to exceed 5 mg), concomitant use of a potent CYP3A4 inhibitor, hiatal hernia/gastroesophageal reflux and/or patients currently taking medicines that can cause or exacerbate dysphagia. Angioedema with airway obstruction has been reported with some patients on Vesicare®. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. **Interactions:** Concomitant medication with other medicinal products with anticholinergic properties may result in more pronounced therapeutic effects and undesirable effects. Allow one week after stopping Vesicare® before commencing other anticholinergic therapy. Therapeutic effect may be reduced by concomitant administration of cholinergic receptor agonists. Can

OSTEOPOROSIS

Calcium pills up heart attack risk

By Madlen Davies

GPs are being encouraged to manage patients at risk of osteoporosis with dietary advice rather than calcium supplements, after a new study found supplements almost doubled the risk of heart attack.

The study of 24,000 people showed those taking vitamin and mineral supplements which included calcium had an 86% increased risk of a heart attack, and those taking calcium-only supplements had a 139% increased risk, compared with those taking no supplements at all.

The evidence adds to previous studies casting doubt on NICE guidance that GPs should consider calcium supplements in all postmenopausal women at risk of osteoporosis.

The study by German and Swiss researchers looked at men and women aged between 35 and 64 years, with no history of cardiovascular problems, and followed them for 11 years.

They found increasing dietary calcium intake reduced the risk of heart attacks.

Women in the third quartile of calcium intake had a 57% lower risk of heart attacks than the first quartile, although no



Calcium supplements can raise women's risk of heart attack

significant effect was seen in men.

Study leader Professor Kuangrong Li, lead researcher in cancer epidemiology at the German Cancer Research Centre, said: 'Calcium supplements, which might raise myocardial infarction risk, should be taken with caution.'

In an editorial, Professor Ian Reid and Professor Mark Bolland, deputy dean and senior research fellow respectively at the Faculty of Medical Sciences, University of Auckland, said the study showed supplementation was 'not natural'.

They added: 'We should return to seeing calcium as an important component of a balanced

diet and not as a low-cost panacea to postmenopausal bone loss.'

Dr Christopher Arden, a GP in cardiology in Eastleigh, Hampshire, said the study's results showed regular exercise and a balanced diet might be more beneficial than supplements.

'The bottom line is that as GPs we have to look at approaches optimising lifestyles,' he added.

A spokesperson for the MHRA said it would 'carefully evaluate' the new study: 'We will provide updated advice if necessary.'

Heart 2012, online 24 May

@madlensdavis

PSORIASIS

Vigorous exercise cuts psoriasis risk in women



Vigorous physical activity in women at risk of psoriasis is associated with a reduced likelihood of the condition developing later in life, according to new research.

The authors analysed a cohort of 86,665 women without psoriasis over a decade. They found the most active women had a 25% decreased risk of psoriasis later in life, compared with the least active women. For the women in subgroups of activity levels between these two,

there was a significant trend towards decreased risk as activity level increased.

When analysing the type of activity, women who undertook vigorous physical activity were 34% less likely to develop psoriasis when compared with less vigorously active women.

Study leader Dr Hillary Frankel, lecturer in dermatology at Harvard Medical School, said: 'Our results suggest vigorous exercise is associated with a 25-30% reduced risk of psoriasis.'

Arch Dermatol 2012, online

21 May

COPD

Acupuncture benefit in COPD



Acupuncture for patients with COPD can have a comparable effect on dyspnoea and exercise capacity to pulmonary rehabilitation, a trial has found.

Japanese researchers looked at 68 patients with COPD and randomised them to receive either acupuncture or placebo acupuncture using blunt needles. Participants had no history of COPD exacerbations and had not undergone pulmonary rehabilitation in the last six months.

After 12 weeks, breathlessness after a six-minute walk, as measured using the Borg scale, had improved from 5.5 to 1.9 in the real acupuncture group, compared with no improvement in the placebo group – a difference that was statistically significant. Oxygen saturation was also significantly improved in the real acupuncture group.

Study leader Dr Masao Suzuki, lecturer in respiratory medicine at Kyoto University, said: 'Our results are comparable with standard care such as rehabilitation or exercise.'

Arch Intern Med 2012, online 14 May



Vesicare®

solifenacin

reduce effects of stimulants of gastrointestinal tract motility. If used concomitantly with ketoconazole or other CYP3A4 potent inhibitors, maximum dose should be 5 mg due to 2-3 fold increase in AUC of Vesicare®. Pharmacokinetic interactions are possible with other CYP3A4 substrates with higher affinity and CYP3A4 inducers. Adverse Effects: Dry mouth, blurred vision, constipation, nausea, dyspepsia, abdominal pain, urinary tract infection, peripheral oedema, colonic obstruction, rash, urinary retention, hallucinations, confusion, state, angioedema. In worldwide postmarketing experience, QT prolongation and Torsade de Pointes have been reported in association with Vesicare® use, but the frequency of events and the role of Vesicare® in their causation cannot be reliably determined. Prescribers should consult the Summary of Product Characteristics in relation to other side effects. Basic NHS Cost: Vesicare® 5 mg blister packs of 30 tablets £27.62; Vesicare® 10 mg blister packs of 30 tablets £35.91. Legal Category: POM. Product Licence Number: Vesicare® 5 mg PL 00166/0157; Vesicare® 10 mg PL 00166/0158. Date of Revision:

October 2011. Further information available from: Astellas Pharma Ltd, 3rd Floor, Future House, The Glens, Egham, Surrey, TW20 9AH. Vesicare® is a Registered Trademark. For full prescribing information please refer to the Summary of Product Characteristics. For medical information phone 0800 783 5018.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Astellas Pharma Ltd, Tel: 0800 783 5018.

Date of preparation: April 2012
VES12142/JK

astellas
Leading Light for Life

CPD
TIP OF
THE
WEEK

Scoring tools good for finding alcohol misuse

Abbreviated alcohol scoring tools – such as CAGE, AUDIT and FAST – are useful for screening for potential alcohol misuse in newly registered patients and as part of chronic disease management, according to a new case-based learning module. Research into the CAGE tool found its sensitivity was greatly enhanced by an open-ended introduction, but greatly reduced when patients were asked about the quantity and frequency of their drinking beforehand.



ONLINE CPD

See the Hot topics in alcohol misuse module at pulse-learning.co.uk

Calm skin. Peaceful night.

Applied regularly, the patient friendly formula of Diprobase will hydrate, soothe and calm eczematous skin¹, helping to reduce night-time itching and scratching.



Diprobase Prescribing Information

Uses: Diprobase Cream and Ointment are emollients, with moisturising and protective properties, indicated for follow-up treatment with topical steroids or in spacing such treatments. They may also be used as diluents for topical steroids. Diprobase products are recommended for the symptomatic relief of red, inflamed, damaged, dry or chapped skin, the protection of raw skin areas and as a pre-bathing emollient for dry/eczematous skin to alleviate drying effects. **Dosage:** The cream or ointment should be thinly applied to cover the affected area completely, massaging gently and thoroughly into the skin. Frequency of application should be established by the physician. Generally, Diprobase Cream and Ointment can be used as often as required.

Please refer to the full SPC text before prescribing this product.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to MSD Pharmacovigilance UK on +44 (0)1992 467272.

Code: CO/14/DERM-1032326-0001 Date of preparation: March 2012 Reference: 1. Diprobase SPC
© Merck Sharp & Dohme Limited, 2012. All rights reserved.

Contra-indications: Hypersensitivity to any of the ingredients. **Side-effects:** Skin reactions including pruritus, rash, erythema, skin exfoliation, burning sensation, hypersensitivity, pain, dry skin and bulous dermatitis have been reported with product use. **Package Quantities:** Cream: 50g tubes, 500g pump dispensers; Ointment: 60g tubes, 500g jar. **Basic NHS Costs:** Cream: £1.28 (50g), £6.32 (500g); Ointment: £1.28 (50g), £5.99 (500g). **Legal Category:** GSL. **Marketing Authorisation Numbers:** Cream: PL 00025/0575; Ointment: PL 00025/0574. **Marketing Authorisation Holder:** Merck Sharp & Dohme Limited, Hertford Road, Hendon, Hertfordshire, BN11 9BU, UK. **Date of Revision:** February 2012.



Diprobase[®]

Emollient

Tried. Trusted. Diprotected.



www.diprobase.co.uk

Size, geography and running costs of the 212 CCGs to be considered for authorisation announced
AUTHORISATION

Final CCGs vary in size 13-fold

By Gareth Iacobucci

The Government has revealed the final names and configurations of the 212 CCGs that will be considered for authorisation, in a move hailed as a 'landmark moment' in the transition to clinical commissioning.

The NHS Commissioning Board last week announced details of the sizes, geography and management allowances of the new organisations that will replace PCTs in England, signalling an end to the recent rush of mergers and reconfigurations.

The 212 CCGs, which must all carry the 'NHS' prefix, cover populations ranging from 68,000 (NHS Corby CCG) to 901,000 (NHS North, East, West Devon CCG), with most somewhere between 150,000 and 300,000.

Some 86 CCGs will match their local authority boundary, with four matching the boundaries of more than one local authority taken together, and a further 95 sitting wholly within a local authority.

Some 27 CCGs will cross lo-

cal authority boundaries, with around half of these crossing at the margins, and the other half crossing boundaries 'in a more substantial way'.

The list also revealed the additional interim management allowance each CCG will receive, calculated according to how many unregistered patients are in each locality, and where patients are likely to access emergency care.

Details of proposed applicants for waves two, three and four of authorisation were also disclosed, ahead of the deadline for submissions from the 35 CCGs in wave one on 1 July.

Dr Michael Dixon, chair of the NHS Alliance and a GP in Cullompton, Devon, said the news provided 'welcome stability' to CCGs.

But he warned: 'This does look dangerously close to the number of PCTs. In terms of leadership they'll look different, but in terms of contact with local practices, the jury's out.'

But Dame Barbara Hakin, national director of commis-



Dame Barbara Hakin: a 'landmark moment' for commissioning

CCGs by numbers
212

 number of CCGs being
 authorised

68,000

 number of patients covered by
 smallest CCG

901,000

 number of patients covered by
 largest CCG

Source: NHS Commissioning Board

sioning development at the NHS Commissioning Board, said although many CCGs would resemble PCTs in geography, there would be 'enormous differences' in how they operated.

She said: 'The differences are more in how they are formed rather than the geographies they cover. This is a real landmark moment.'

@garethiacobucci

INTERACTIVE MAP
 See all 212 CCGs

pulsetoday.co.uk/commissioning
COMMISSIONING SUPPORT

Charities to support CCGs

A group of leading charities has been selected to spearhead a Government pilot to offer commissioning support to CCGs, in a move that could pave the way for greater involvement from the voluntary sector in commissioning.

The Rheumatology Commissioning Support Alliance, a partnership between the British Society of Rheumatology, the National Rheumatoid Arthritis Society and Arthritis Care, has been chosen to take part in a new Department of Health pilot.

The move comes despite Pulse revealing in January that the Stroke Association had pulled out of plans to provide commissioning support, having decided it did not have the capacity to cope with the com-

plexities of the process.

The group of charities pledged to provide 'professional, expert commissioning support services' to GP commissioners, and said specialist knowledge was 'urgently needed' to ensure services were commissioned more effectively.

Dr Michael Dixon, chair of the NHS Alliance, said: 'Charities will be very useful for commissioners as long as we know where they're coming from. There's a risk that they could upset priorities set by the CCG as they're only interested in their area and might want to slant budgets in that direction.'

'But they have more detailed knowledge of one area and can offer innovative commissioning.'

PRIMARY CARE

Local focus for GP services

GP services are to be commissioned by local teams of managers after the NHS Commissioning Board delegated responsibility to them.

Minutes from the NHS Commissioning Board's May meeting reveal it plans to discharge some £22bn worth of direct commissioning responsibilities, with 'all local area teams taking on direct commissioning responsibilities for GP services, dental services and pharmacy services'.

It said the new structure would result in a 'significant reduction' from the 50 local offices of the board initially proposed, to a smaller number of local

teams that would each oversee a handful of CCGs.

The board revealed a third of local area teams across England would lead on specialised commissioning, with a smaller number carrying out the direct commissioning of optometric services, military health services and offender health services.

The smaller teams will also commission public health services and interventions, with 'some most likely commissioned on a larger geography than individual local teams (such as screening programmes) and others possibly at individual local area team level (such as public health and under-fives)'.

Some UK hospitals are using this probiotic yogurt drink in those at risk of antibiotic-associated diarrhoea and *C. diff*-associated diarrhoea...



...could it help your at risk antibiotic patients too?

Probiotics have been shown to help restore the balance of gut bacteria disturbed by antibiotic use.^{1,2} Actimel is a probiotic yogurt drink, containing *Lactobacillus casei* DN-114 001*, which has been shown to support the body's immune system in numerous clinical studies³. In one clinical study older hospitalised patients (over 50 years of age) drinking Actimel daily⁴ during a course of antibiotics and for one week after showed significantly reduced incidence of antibiotic-associated diarrhoea and *C. difficile*-associated diarrhoea.⁵ WGO Practice Guidelines report 'Recent research has indicated that *L. casei* DN-114 001* is effective in hospitalised adult patients for preventing antibiotic-associated diarrhoea and *C. difficile* diarrhoea'.⁶ Some hospitals near your practice have already started integrating it into their *C. difficile* management plans.

Visit www.probioticsinpractice.co.uk to see the evidence for yourself and register for a new RPS accredited CPD e-learning module on probiotics, the immune system and gut microbiota.

Information for Healthcare Professionals

* *Lactobacillus casei* DN-114 001/CMC-11518 (L. casei Danone)
 † Two bottles consumed daily

References: 1. De La Coeurde NF et al. *Microb Drug* 2008;50:395-402. 2. O'Toole PW and Cooney JJ. *Antonie van Leeuwenhoek* 2008; 175-180. 3. Danone Research. Clinical studies - Actimel publications. Available online at: www.studies.danone.com (accessed August 2011). 4. Hickson M et al. *BMJ* 2007;335:90. 5. World Gastroenterology Organisation. Practice Guidelines: Probiotics and Prebiotics. May 2008. Available online at: www.worldgastroenterology.org/probiotics-probiotics.html (accessed August 2011).

JH030 May 2012



Ca effect to beef up aspirin role

DH consults with NICE and MHRA over how to use aspirin to reduce cancer risk

By Nigel Praities

The Department of Health is looking at the 'next steps' for beefing up the role of aspirin in clinical guidelines, after an analysis showed 'clinically meaningful' reductions in cancer mortality after just four years of taking the drug.

The move comes after several studies showed aspirin use was associated with a reduction in cancer deaths, and raises the prospect of a surprising about-turn for the drug, which is in the

process of being written out of many cardiovascular guidelines.

The DH said it was working with the MHRA, NICE and leading cancer charity Cancer Research UK in drawing up its response to the mounting positive data for aspirin.

NICE is currently reviewing its recommendation of low-dose aspirin for primary prevention in diabetes, with some experts suggesting the effect on cancer risk should be taken into account when treating people at high cardiovascular risk.



Aspirin was found to reduce deaths from cancer by 23%

The new meta-analysis - published in June's *American Journal of Medicine* - found a 23% reduction in cancer mortality in patients taking aspirin, compared with controls not taking the treatment. Researchers showed for the first time that significant protective effects could be observed after an average of just four years of follow-up.

They pooled data from 21 randomised studies and 16,000 patients, and found 162 cancer deaths in the group taking aspirin (2%), compared with 210 in controls (2.6%).

Study leader Professor Edward Mills, global health research chair for the Canadian government, said: "These findings should be useful for counselling low- and high-risk patients with cardiovascular disease. It seems likely aspirin will now be the backbone of cancer prevention strategies."

A DH spokesperson said: "We are working with the MHRA, NICE and Cancer Research UK to consider the next steps on the benefits of aspirin on preventing cancer."

NICE said: "Use of aspirin for primary prevention of cardiovascular events will be considered in light of new evidence."

In contrast, the European So-

Reduction in cancer mortality with aspirin

Months on aspirin	Cancer mortality risk
36	0.82
42	0.78
52	0.79
72	0.76
80	0.77

Source: *Am J Med* 2012;125:560-7

ciety of Cardiology this month removed aspirin from its guidelines as an option for primary prevention of cardiovascular events, following a similar move in Scotland in 2010.

Dr Willie Hamilton, senior research fellow in primary health-care at the University of Bristol and a GP in the city, said: "There seems little doubt aspirin reduces cancer incidence, and some suggestion it reduces metastasis. However, the downside of haemorrhage is real. I don't think it's quite ready for GP recommendation yet, though I suspect it will be in time."

► @nigelpraities

SEMINAR
Diabetes Update 2012
pulse-seminars.com

Help put migraine behind her

A long lasting triptan for sustained migraine relief

migard
frovatriptan

Migard 2.5mg film-coated tablets (frovatriptan)
Abbreviated Prescribing Information Please consult the Summary of Product Characteristics (SPC) for full prescribing information. **Presentation:** Film-coated tablets containing 2.5mg frovatriptan. Contains lactose. **Use:** Acute treatment of the headache phase of migraine attacks with or without aura. **Dosage:** Oral administration. Adults: 2.5mg. Max 5mg in 24 hours. Not recommended for use in children, adolescents, patients over 65 and patients with severe hepatic impairment. **Contra-indications:** Hypersensitivity, history of myocardial infarction, ischaemic heart disease, coronary vasospasm, peripheral vascular disease, signs of ischaemic heart disease. Severe, moderately severe or uncontrolled hypertension. Previous cerebrovascular accident or transient ischaemic attack, severe hepatic impairment, concomitant administration with ergotamine, ergotamine derivatives or other 5-HT₁ receptor agonists. **Warnings and Precautions:** Establish clear diagnosis. Do not use for hemiplegic, basilar or ophthalmic migraine. In common with other 5-HT₁ agonists, care with coronary artery disease, heavy smokers, users of nicotine substitution therapy. Specific attention to post-menopausal women and men over 40 years of age with these risk factors. Very rare cases of serious cardiac events in patients with no underlying cardiovascular disease. Allow 24 hours between doses of frovatriptan and ergotamine-type medications. Overdose can lead to increased side-effects. Prolonged use of painkillers for headaches can make them worse. Contains lactose, therefore, do not give to patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose

malabsorption. Concomitant use with St John's wort, pregnancy and lactation. **Interactions:** Ergotamine and ergotamine derivatives, monoamine oxidase inhibitors. Please consult the SPC for other interactions. **Side-effects:** Common (1-10%): dizziness, paraesthesia, headache, somnolence, dysaesthesia, hypoaesthesia, visual disturbance, flushing, throat tightness, nausea, dry-mouth, dyspepsia, abdominal pain, hydroedema, fatigue, chest discomfort. Uncommon (0.1-1%): Dehydration, anxiety, insomnia, confusion, drowsiness, agitation, depression, depersonalisation, dyspepsia, inner disturbance in attention, lethargy, hyperaesthesia, vertigo, vertigo, involuntary muscle contractions, eye pain, eye irritation, photophobia, frontal, ear pain, palpitations, tachycardia, peripheral oedema, hypertension, rhinitis, sinusitis, pharyngolaryngeal pain, diarrhoea, dysphagia, flatulence, stomach discomfort, abdominal discomfort, pruritus, musculoskeletal stiffness, musculoskeletal pain, pain in the extremity, back pain, arthralgia, paresthesia, paresthesia, chest pain, feeling hot, temperature intolerance, pain, asthma, thirst, sluggishness, energy increased, malaise. Rare (0.1-0.01%): Lymphadenopathy, hypotension, abnormal dreams, personality disorder, amnesia, hypertension, hyperhidrosis, movement disorder, night blindness, ear discomfort, ear discharge, ear pruritus, hyperacusis, tachycardia, apnoea, hiccup, hyperventilation, respiratory disorder, throat irritation, constipation, emetion, gastroesophageal reflux disease, infantile bowel syndrome, lip Nider, lip pain, oesophageal spasm, oral mucosal blistering, peptic ulcer, salivary gland pain, stomatitis,

boothache, erythema, pleurodynia, purpura, urticaria, nocturia, renal pain, breast tenderness, pyrexia, blood bilirubin increased, blood calcium decreased, uric acid analysis abnormal. Unknown frequency: hypersensitivity reactions including cutaneous disorders and anaphylaxis. **Package quantities and price:** 6 tablets: £18.67. **Legal category:** POM. **Marketing Authorisation Number:** PL 16236/0017. **Marketing Authorisation holder:** Menarini International Operations Luxembourg S.A. **Marketed by:** A. Menarini Pharma U.K. S.R.L. Further information is available on request to A. Menarini Pharma U.K. S.R.L. Menarini House, Mercury Park, Wycombe Lane, Westbury Green, Buckinghamshire, HP10 8HH, UK or may be found in the SPC. Last updated: October 2008.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to A. Menarini Pharma U.K. S.R.L. Phone no. 0800 085 8678

Date of preparation: August 2011

3765AM04/JUG/2011/CPL

Migard® is a registered trademark of A. Menarini Pharma U.K. S.R.L.



Trial of HPV tests before smears

The Department of Health is to test plans to replace smear tests as the primary screening method for cervical cancer, after its advisers said HPV testing might be a better indicator of risk.

The move comes after studies showed using HPV testing as the initial screen detected more women with potentially cancerous lesions than using smear tests.

If successful, the pilot would reverse the approach to screening currently being rolled out in

England, as cytology would only be conducted if a sample tested positive for HPV.

The National Screening Committee said: "The pilot will look at whether this leads to better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally."

Dr Anne Mackie, director of the committee, said: "HPV testing may better indicate which women are at risk of cervical cancer."

IN BRIEF

QOF smoking errors

GPs have uncovered a series of errors in the business rules on QOF smoking indicators.

Full story ► pulsetoday.co.uk/clinicalnews

College's HQ unveiled

The RCGP has unveiled its £34m glass-enclosed headquarters near Euston station in London in a ceremony for members and fellows.

Full story ► pulsetoday.co.uk/practicenews

NICE advice on opioids

NICE has produced guidelines to tackle GPs' reluctance to prescribe opioids as part of palliative care.

Full story ► pulsetoday.co.uk/clinicalnews

FOR PATIENTS WITH TYPE 2 DIABETES

NEW UK RENAL LICENCE: WORLDWIDE RENAL EXPERIENCE

THE MOST WIDELY PRESCRIBED DPP-4 INHIBITOR WORLDWIDE¹

TOTAL PRESCRIPTIONS DISPENSED WORLDWIDE²

JANUVIA 100mg:
STANDARD DOSE*

> 24.5 MILLION

JANUVIA 50mg:
RENAL DOSE
MODERATE RENAL IMPAIRMENT**

> 4.3 MILLION

STUDIED IN OVER 650 PATIENTS WITH RENAL IMPAIRMENT^{3,4,5}

* For patients with creatinine clearance ≥ 50 ml/min

** For patients with creatinine clearance ≥ 30 to <50 ml/min

JANUVIA can be used as monotherapy in patients contra-indicated to or intolerant of metformin when diet and exercise does not provide adequate glycaemic control; or added on to metformin, a glitazone, a sulphonylurea, a stable dose of insulin (with or without metformin), metformin + a sulphonylurea, or metformin + a glitazone, when the current regimen plus diet and exercise does not provide adequate glycaemic control.



Prescribing Information can be found overleaf



JANUVIA® (sitagliptin)

PRESCRIBING INFORMATION

Refer to Summary of Product Characteristics (SPC) before prescribing

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to MSD (tel: 01992 467272).

PRESENTATION

25 mg film-coated tablet containing 25 mg of sitagliptin
50 mg film-coated tablet containing 50 mg of sitagliptin
100 mg film-coated tablet containing 100 mg of sitagliptin.

USES

For adult patients with type 2 diabetes mellitus (Januvia®) is indicated to improve glycaemic control.

as monotherapy

In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with

metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.

a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.

a PPAR γ agonist (i.e. a thiazolidinedione) when use of a PPAR γ agonist is appropriate and when diet and exercise plus the PPAR γ agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with

a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

a PPAR γ agonist and metformin when use of a PPAR γ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.

DOSAGE AND ADMINISTRATION

One 100 mg tablet once daily, with or without food. When sitagliptin is used in combination with metformin and/or a PPAR γ agonist, maintain the dosage of metformin and/or PPAR γ agonist, and administer sitagliptin concomitantly. When used in combination with a sulphonylurea or with insulin, consider a lower dose of sulphonylurea or insulin, to reduce risk of hypoglycaemia. If a dose of Januvia is missed, take as soon as the patient remembers. Do not take a double dose on the same day.**Renal impairment:** when considering use in combination with other anti-diabetic products, check conditions for use in patients with renal impairment. No dosage adjustment required for mild renal impairment (creatinine clearance [CrCl] ≥ 30 mL/min). For patients with moderate renal impairment (CrCl ≥ 30 to < 30 mL/min), the dose of Januvia is 50 mg once daily. For patients with severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Januvia is 25 mg once daily. Januvia may be administered without regard to the timing of dialysis. Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Januvia and periodically thereafter. **Hepatic impairment:** no dosage adjustment necessary for patients with mild to moderate hepatic impairment. Januvia has not been studied in patients with severe hepatic impairment. **Elderly:** no dosage adjustment necessary. Exercise care in patients > 75 years of age as there are limited safety data in this group. **Children:** not recommended in children below 18 years of age.

CONTRA-INDICATIONS

Hypersensitivity to active substance or excipients.

PRECAUTIONS

General: do not use in patients with type 1 diabetes or for diabetic ketoacidosis.**Pancreatitis:** Post-marketing experience - spontaneously reported adverse reactions of acute pancreatitis. Inform patients of the symptoms of acute pancreatitis: persistent, severe abdominal pain. Resolution of pancreatitis has been observed after discontinuation of sitagliptin, but very rare cases of reoccurring or haemorrhagic pancreatitis and/or death have been reported. If pancreatitis is suspected, Januvia and other potentially suspect medicinal products should be discontinued.**Hypoglycaemia when used with other anti-hyperglycaemic agents:** Cases of hypoglycaemia reported with sitagliptin were generally similar to rates in patients taking placebo. When sitagliptin was added to a sulphonylurea or to insulin, the incidence of hypoglycaemia was increased over that of placebo; therefore consider a lower dose of sulphonylurea or insulin to reduce the risk of hypoglycaemia. **Renal impairment:** Januvia is renally excreted. To achieve plasma concentrations of Januvia similar to those in patients with normal renal function, lower dosages are recommended in patients with moderate and severe renal impairment, as well as in ESRD patients requiring haemodialysis or peritoneal dialysis (see section 'Dosage and administration' above and section 4.2 and 5.2 of the SPC). **Hypersensitivity reactions:** Serious hypersensitivity reactions have been reported, including anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset occurred within the first 3 months after initiation of treatment with some reports occurring after the first dose. If suspected, discontinue

Januvia, assess for other potential causes and institute alternative treatment for diabetes.

Drug interactions

Low risk of clinically meaningful interactions with metformin and ciclosporin. Meaningful interactions would not be expected with other p-glycoprotein inhibitors. The primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.

Digoxin: sitagliptin had a small effect on plasma digoxin concentrations, and may be a mild inhibitor of p-glycoprotein in vivo. No dosage adjustment of digoxin is recommended, but monitor patients at risk of digoxin toxicity if the two are used together.

Pregnancy and lactation: Do not use during pregnancy or breast-feeding.

SIDE EFFECTS

Refer to SPC for complete information on side effects

Sitagliptin monotherapy: Common ($\geq 1/100$ to $< 1/10$): upper respiratory tract infection, nasopharyngitis, otitis media, pain in extremity, hypoglycaemia, headache. Uncommon ($\geq 1/1,000$ to $< 1/100$): dizziness, constipation. **Combination with metformin:** Common ($\geq 1/100$ to $< 1/10$): hypoglycaemia, nausea, flatulence, vomiting. Uncommon ($\geq 1/1,000$ to $< 1/100$): asthenia, constipation, upper abdominal pain, diarrhoea, blood glucose decreased. **Combination with a sulphonylurea:** Common ($\geq 1/100$ to $< 1/10$): hypoglycaemia. **Combination with metformin and a sulphonylurea:** Very common ($\geq 1/10$): hypoglycaemia; Common ($\geq 1/100$ to $< 1/10$): constipation. **Combination with a PPAR γ agonist (thiazolidinedione):** Common ($\geq 1/100$ to $< 1/10$): hypoglycaemia, flatulence, peripheral oedema, blood glucose decreased. **Combination with a PPAR γ agonist and metformin:** Common ($\geq 1/100$ to $< 1/10$): upper respiratory tract infection, headache, diarrhoea, vomiting, hypoglycaemia, peripheral oedema, cough; Uncommon ($\geq 1/1,000$ to $< 1/100$): fungal skin infection. **Combination with insulin with/without metformin:** Common ($\geq 1/100$ to $< 1/10$): headache, hypoglycaemia, influenza. Uncommon ($\geq 1/1,000$ to $< 1/100$): dry mouth, constipation.

Adverse events with sitagliptin alone in clinical studies, or during post-approval use alone and/or with other diabetes medicines where frequency is not known: hypersensitivity reactions including anaphylactic responses (see section 4.4), interstitial lung disease, vomiting, acute pancreatitis, fatal and non-fatal haemorrhagic and necrotising pancreatitis, angioedema, rash, urticaria, cutaneous vasculitis, exfoliative skin conditions including Stevens-Johnson syndrome, arthralgia, myalgia, impaired renal function, acute renal failure.

† Based on incidence regardless of causal relationship.

‡ Adverse reactions were identified through postmarketing surveillance.

§ 54-week time point.

|| See precautions.

PACKAGE QUANTITIES AND BASIC NHS COST

28 Tablets: £33.26

Marketing Authorisation Number

EU/1/07/383/002 - Januvia 25 mg tablets

EU/1/07/383/008 - Januvia 50 mg tablets

EU/1/07/383/014 - Januvia 100 mg tablets

Marketing Authorisation Holder

Merck Sharp & Dohme Limited

Hertford Road, Hertfordshire, Hertfordshire EN11 8BU, UK

POM Date of review of prescribing information: March 2012

© Merck Sharp & Dohme Limited, 2012. All rights reserved.

PL/AN/ALL/12/UK/3615

References:

1. Data on file.
2. NHS Health, NPS Monthly, Tires, October 2006 - November 2011.
3. Ferreira JCA, et al. Efficacy and Safety of Sitagliptin versus Glipizide in Patients with Type 2 Diabetes and Moderate to Severe Chronic Renal Insufficiency, PN 063, Poster, 2011 EASD.
4. Ferreira JCA, et al. Efficacy and Safety of Sitagliptin vs. Glipizide in Patients with Type 2 Diabetes Mellitus and End-stage Renal Disease on Dialysis: A 54-week Randomised Trial, PN 073, Poster, 2011 EASD.
5. Chan JCN et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity and Metabolism, 10: 545-555, 2008.

A tangle of IT contradictions

It's been a week when ministers finally flicked the off-switch on one troubled IT project, and appeared to accept another was being superseded by something sleeker and more modern. The previous government's flagship HealthSpace site became an early casualty of the coalition's information strategy. Ministers are just as keen as their predecessors to see online access to medical records and email access to practices - but it's going to be done at a pace, and to a specification, that fits GP needs. And the needs are there - some GPs are already exploring use of Skype for online consultations, outside the auspices of any Government IT project.

Then there's the Summary Care Record - the 100-million pound IT project to eat them all. It officially continues to hum along, like some giant, room-sized prototype computer. But the care record was mysteriously absent from the information strategy, and IT enthusiasts and sceptics alike are declaring it has been rendered largely redundant by the rampaging technological advances of the private EMIS Web system.

All this is consistent with the Government's ideological acceptance that a series of independent providers of IT systems are far more likely to quickly and effectively meet the needs of users than a giant, centrally dictated programme. So have we seen the end of health IT systems being imposed upon general practice from on high? Sadly, not just yet.

Over the last few months, Pulse has been tracking the slow decline of another unwieldy Government IT system - Choose and Book. GPs made perfectly plain their distaste for Choose and Book right from the start, so it should hardly have come as a surprise that once payments for its use disappeared, so did

referrals through it - down from 57% in 2010 to just 50% now. The Government's response, according to its new doctrine of 'user knows best', should surely have been to open up the market to new providers of choice-based referral systems, that maybe were user-friendly enough not to need delegating to the receptionist. Instead, in the same week the Government released its information strategy, it put out a new document on choice - threatening that GPs who did not use Choose

and Book would be forced to phone round providers individually to check appointment availability.

'Where Choose and Book is not being used, formal requirements to support greater choice for patients will have to be met by alternative - potentially labour-intensive - methods,' the document stated, ominously.

So one moment GPs are sufficiently IT-literate to make informed choices over systems for electronic records and online consultations - the next they are the recipients of blunt threats over Choose and Book. The Government's IT policy remains a tangle of logical contradictions.

Richard Hoey
Editor

Saying goodbye

I leave Pulse this week after eight years here, the last three as editor. It has been an immense privilege to put together a publication for general practice, and to have the chance to meet and speak to so many of those GPs who make it the great profession it is. I have found general practice to be warm, funny, passionate and never short of an opinion, and I shall miss it enormously.

Let us know your views by emailing Pulse at editor@pulsetoday.co.uk

How to contact Pulse

General editorial enquiries

020 7332 2904

or email bec.rabe@briefingmedia.com

News desk

020 7332 2904

Classified advertising

020 7332 2924

Display advertising

020 7332 2928

pulsetoday.co.uk

020 7332 2938

Email pulse@pulsetoday.co.uk

Address (editorial)

Pulse, Briefing Media, 3rd Floor

Marshall House, 2 Purkiss Dock,

London EC4V 3DB

Delivery and subscription

Medical Reader, c/o BHP, 2-3

Commercial Way, Christy Close,

Southfields, Basildon SS16 6EP

Free circulation: Call 0845 1369316

or email medicalreader@binkys.comor email bec.rabe@briefingmedia.comor email pulse@pulsetoday.co.ukor email bec.rabe@briefingmedia.comor email pulse@pulsetoday.co.ukor email bec.rabe@briefingmedia.comor email pulse@pulsetoday.co.uk

Paid subscription: Call 01858 438893

or email bec.rabe@briefingmedia.com

Editor Richard Hoey

Group editor Jo Haynes

Deputy editor Steve Nowotny

Group clinical editor Adam Legge

Deputy news editor Nigel Pretties

Chief reporter Gareth Jacobucci

News intern Maclen Davies

Online producer Jessica Baron

Online intern Hannah Bass

Deputy clinical editor

Rhianon Smith

Assistant clinical editor David Swan

Assistant features editor

Ellie Broughton

Art director Ravi Naidoo

Art editor James Daphne

Senior sub editor Brooke Balza

Events and business editor

Lisa Thomlinson

Editorial adviser Dr Keith Hopcroft

General practice adviser

Dr Alistair Moulds

Production controller Phil Taylor

Advertising executive Cliff Brown

Head of events Stephen Knowles

Projects director Paul Bernesem

Associate publisher

Sarjay Chudasama

CEO, Briefing Media Neil Thackray

CMO, Briefing Media Rory Brown



Xifaxanta™ gets to work here
...and only here^{1,2}

The first and only virtually
non-absorbed antibiotic licensed
for the treatment of non invasive
Travellers' Diarrhoea³



Xifaxanta™
Rifaximin- α

XIFAXANTA™ Prescribing Information

REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) BEFORE PRESCRIBING.

Presentation: Film-coated tablet containing rifaximin 200 mg. **Uses:** Xifaxanta is indicated for the treatment of travellers' diarrhoea that is not associated with fever, bloody diarrhoea, eight or more unformed stools in the previous 24 h, occult blood or leucocytes in the stool. **Dosage and administration:** Adults over 18 years of age: 200 mg every 8 hours for three days (total 9 doses). Rifaximin must not be used for more than 3 days even if symptoms continue and a second course of treatment must not be taken. Not recommended in children under 18 years of age. **Contraindications:** Hypersensitivity to the active substance, to any rifamycin (e.g. rifampicin or rifabutin) or to any of the excipients. **Warnings and precautions for use:** Not recommended for the treatment of travellers' diarrhoea caused by invasive enteric pathogens. If symptoms worsen, treatment with rifaximin should be interrupted. If symptoms have not resolved after 3 days of treatment, or recur shortly afterwards, a second course is not recommended. The potential association of rifaximin treatment with *Clostridium difficile* associated diarrhoea and pseudomembranous colitis cannot be ruled out. **Interactions:** Due to the

negligible gastrointestinal absorption of orally administered rifaximin (less than 1%), the systemic drug interaction potential is low. Rifaximin should not be administered concomitantly with other rifamycins and the tablets should not be administered for at least two hours after the administration of charcoal. **Pregnancy and lactation:** Rifaximin is not recommended during pregnancy and in women of childbearing potential not using contraception. The benefits of rifaximin treatment should be assessed against the need to continue breastfeeding. **Undesirable effects:** Common effects reported in clinical trials are dizziness, headache, abdominal pain, constipation, defecation urgency, diarrhoea, flatulence, bloating, distension, nausea, vomiting, rectal tenesmus and pyrexia. Other effects that have been reported are candidiasis, herpes simplex infections, clostridial infections, palpitations, increased blood pressure, liver function test abnormalities, blood disorders (e.g. thrombocytopenia) and anaphylactic reactions, e.g. angioedema, hypersensitivity and skin reactions). **Licensing and legal category:** Legal category: POM. **Cost:** Basic NHS price £15.15 (9 tablets). **MA number:** PL 20011/0021. **For further information contact:** Norgine Pharmaceuticals Limited,

Norgine House, Moorhall Road, Harefield, Middlesex, UB9 6NS. 01895 826606. E-mail: medinfo@norgine.com. **Date of preparation/revision:** XIF/2353/AUG/11.

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk>. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606.

References

1. Jiang ZD et al. *Antimicrob Agents Chemother* 2000;44 (8):2205-2206.
2. Descombe JJ et al. *Int J Clin Pharmacol Res* 1994;14 (2):51-56.
3. Xifaxanta™ Summary of Product Characteristics.



XIF/2620/SEP/11.

XIFAXANTA is a trademark of Alfa-Wassermaier Hungary KFT, exclusively licensed in the UK to the Norgine group of companies.

Date of preparation: September 2011.

14 Phil Peverley

Yes, it *might* be lung cancer

If we got every minor symptom looked at, we'd spend our lives in our GP's surgery, Phil says

If you have a cough for more than three weeks, you might have lung cancer and so you should see your GP. So says a current advertising campaign, funded by the NHS, which appears on most websites I visit.

'If you've been coughing for over three weeks, it might not be "only a cough". So tell your doctor,' it says. Then you get a picture of Dr Ian Watson, who may or may not be real and who may or may not be the author of those words, but who is certainly in the 'chiselled jaw and stethoscope round the neck' class with Dr Hilary Jones and his ilk. The type who divide their time between the surgery, the sofa on breakfast TV, and having daily handsome lessons.

Of course, he could be right. It *might* be lung cancer. It just probably isn't. More probably for some than for others - this week I had to reassure the mother of an eight-year-old that his three-week cough might need some treatment, but not an X-ray at this stage and certainly not chemotherapy. I think she was already picturing him bald, at Disneyland.

Don't get me wrong, I'm not knocking

this campaign. We are not good, in the UK, at picking up lung cancer while it is still in the operable phase - which is odd when you think about how much industrial lung disease we have suffered, as a nation. Perhaps subconsciously we feel that a bit of 'inflammation o' t'lungs' is just one of those manly things that working-class blokes get. Blood-stained phlegm? Just spit it into the coal fire and make it sizzle.

While looking up a bit of background on this campaign, however, I got a sobering insight into what can potentially happen if we follow every minor symptom to its logical conclusion. The Benenden Healthcare Society (and I should point out here that Benenden exists purely to sell private health insurance) has surveyed 2,000 people and discovered that we will each suffer an average of 9,762 ailments or injuries in our lifetimes. As we're each attending our GP's surgery about 400 times during our lives, it seems difficult to comprehend how we might fit them all in. That's over 24 complaints per consultation, which seems excessive even in those surgeries that offer 15-minute appointments. Perhaps not all are worthy of a doctor's appointment.

I think she was picturing him bald, at Disneyland

Deeper analysis makes this look more likely. You'll have 2,808 bumps or bruises during your time on this earth. You'll have blocked sinuses 312 times, and heartburn exactly the same number of times. Someone else appears to be having all my sinus trouble, but I'm shouldering at least four of my fellow citizen's acid reflux.

You'll suffer 234 shaving cuts, which seems excessive. I've done it twice, so the rest of you please shave only when sober and not during parachute jumps. You'll also crick your neck 318 times, have 468 'stomach upsets' (different from heartburn, then) and an astonishing 78 eye infections. I'll put my reputation on the line and call that one a lie.

One quarter of us admit to having stepped on an electric plug and hurt their foot. Presumably the rest of us were too pissed to remember, because *everyone* has done that. Only a bit of discarded Lego is more painful in the dark.

The spokesperson from Benenden advises us that the human body takes a terrible daily bashing, and his advice is 'washing hands regularly, maintaining good posture, eating healthily and exercising to stay fit and well'.

Thanks for that, spokesperson. Another finding of your survey, although one that you did not publish, is that the number of average deaths suffered by humans remains at one, and is not likely to change any time soon, no matter how good our posture might become.

Dr Phil Peverley is a GP in Sunderland

Margaret McCartney

Wake up to perils of awareness



Most awareness campaigns can prove only that people have become more aware of the campaign, Margaret warns

I can't be the only GP who has noticed an awful lot of coughing. There is a new urgency and a new concern, though - cancer. True, we've always known that a persistent cough can be a sign of serious underlying disease. And certainly, a chronic cough needs medical attention. But is a new NHS awareness campaign - 'Be clear on cough' - going to do us any favours?

The '3 week cough' campaign has a website, which starts off by asking: 'Has someone you love had a cough for three weeks or more?' (It doesn't say what to do if they're not very lovable.) 'It might be something more serious,' it says, followed by: 'Don't take any excuses - they may need a chest X-ray, even if they've had one before... Help stop their cough and put an end to their worry.'

That's curious, because no one seemed to be worried before they were told to get to the doctor with no excuses. Even more curious is the assertion that 'a chest X-ray is a quick and easy way to find out if everything is okay'.

So what's based in evidence? Do we know,

first of all, that awareness campaigns work? When asked, most campaigns will deliver evidence that shortly after the money was spent on advertising, more people had heard of the campaign. But what's really needed is evidence that the campaign led to meaningful improvements in quality and quantity of life, for instance through better interventions for easier-to-treat cancer.

The evidence provided by the Department of Health for this campaign rests on a pilot scheme that showed more people had heard of the campaign and that there were 'extra' attendances for cough eight weeks after the advertising.¹

The number of chest X-rays ordered went up - but did this help detect cancers earlier? A pilot in Doncaster suggests more lung cancers can be picked up in areas subjected to an awareness campaign.² Before the campaign, the rate of lung cancer detection in the control group was 108 per 100,000; the intervention group's was 88 per 100,000. The rate after the campaign was 97 in the control group and 112 in the intervention group. The abstract proclaimed a '27% increase in lung cancer diagnoses in the intervention area'.

Money spent on campaigns comes from somewhere

compared with a fall in the control areas', but the variable base rates, I think, mean it is difficult to make a definite conclusion about the value of it. We must also account for lead time bias when trying to assess how useful campaigns like this are - we might only be detecting cancers a matter of weeks earlier. Indeed, so far the Doncaster data has shown that more lung cancers are being diagnosed at stages III and IV. Not the earlier diagnosis that was hoped for.

How frequently does a cough mean lung cancer? Not often: a 2005 study from Bristol suggested just over half the presentations of lung cancer involve a cough.³ However, when people are sent questionnaires, around 12% of the population say they have a chronic cough,⁴ and less than 2% of people seeing their doctors about a chronic cough will be diagnosed with lung cancer.⁵

As for chest X-rays, they will miss lung cancers around a quarter of the time.⁶ So with the sizable false negative rate, is this marketing campaign and all the effort attached to it - including prerecorded coughs as part of adverts in bus shelters - really the best we can do to reduce the suffering caused by lung cancer? I don't think so - and of course money spent on awareness campaigns has to come from somewhere. I'm concerned that only the least ill will pay attention to them. When it comes to awareness campaigns, we need better evidence than this.

Dr Margaret McCartney is a GP in Glasgow

References

- 1 NHS. Cough. 2012. 3weekcough.org/whattodo.html
- 2 Department of Health. Lung Cancer Awareness Campaign cluster briefing slide pack. 2012
- 3 Athey V, Suckling B, Tadi A et al. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. *Thorax* 2012;67:412-7
- 4 Hamilton W, Peters T, Bound A et al. What are the clinical features of lung cancer before the diagnosis is made? A population-based case-control study. *Thorax* 2005;60:1059-65
- 5 Ford A, Forman D, Moayyedi P et al. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. *Thorax* 2006;61:975-9
- 6 Stapley S, Sharp D and Hamilton W. Negative chest X-rays in primary care patients with lung cancer. *Br J Gen Pract* 2006;56:570-3

Pharmacist interventions won't solve script errors

A flawed analysis of prescribing errors has damaged the reputation of general practice, says **Dr Mark Ironmonger**

On 2 May, the national headlines wallowed in how bad we GPs are at prescribing. According to the BBC, GPs were 'making too many errors prescribing drugs'. The *Daily Mail* said our drug mistakes had hit 40% of the elderly, and the *Daily Express* put one in six patients at risk from our 'blunders'. Little wonder GPs took a pasting, given the responses from our professional representatives about the need for 'improvement' (from the GMC) and 'more GP training' (from the RCGP). But are the 'errors' really errors?

Many of the moderate errors recorded in the PRACTICE study were actually a result of poor medicine at a minority of practices leading to bad prescribing rather than systematic prescribing errors. This was particularly apparent in the list of scenarios subject to a root cause analysis.

Of the 11 serious errors found, there were two obvious allergies that should have been flagged up by an effective use of IT. The other nine were down to inadequate INR monitoring, with eight of these from one practice involving three patients who clearly did not wish to comply with the district general hospital-run INR clinic. The study rightly stated that warfarin prescribing without access to INR test results was 'the most important problem identified' - but failed to highlight that this was largely at one practice.

Some 69% of errors were down to 'failure to request monitoring', which is not a black and white issue, and is subject to change. For example, simvastatin was cited as responsible for 10.5% of prescribing errors and 18.2% of monitoring errors. We don't know if these errors were due to a lack of biochemical monitoring - even though 'fire and forget' is considered a legitimate strategy by NICE once efficacy and two sets of normal LFTs have been established - or whether the errors were due to a failure to specify 'use at night', which some consider of limited significance anyway, and does not apply to some other statins. There is a legitimate argument to say it is more important that the patient takes the medication when they remember.


As a dispensing doctor, I have a natural interest in the prescribing and dispensing accuracy of dispensing practices. Of the report's 227 pages, unfortunately, only one discusses dispensing practice.

This concluded well-trained practice dispensers are a useful defensive strategy against prescribing errors. Dispensers are described as mitigating 'the loss of the safety barrier [of a pharmacist]'. As well as screening prescriptions for errors, dispensers play a useful role in converting Latin prescription instructions into English for patients, and in identifying patients who need monitoring

or medication review. A key contribution to patient safety is the dispenser's ability to make annotated changes on the practice computer system.

GP as well as pharmacy representatives leapt on the report's conclusions that pharmacist-led interventions, particularly medication review, have value in preventing prescribing errors.

Yet the report's own update of a systematic review of primary care interventions found pharmacist-led interventions were not effective at reducing hospital admissions and suspected adverse drug events. It added that because community pharmacists' interventions were not routinely documented on the patient's medical record, this could lead



to errors being propagated to subsequent prescriptions.

Collaborative working with pharmacists brings benefits to patients. But before we embark on initiatives that may cost the NHS more than they save, we must be sure of the evidence base - and that must include a study of dispensing errors made by pharmacists. This report hands the press another stick with which to beat general practice. If the three patients from one practice who would not comply with INR monitoring are taken out of the equation, we are left with three serious errors, and none that caused harm to patients, out of 6,048 GP-issued prescriptions.

Our representative bodies should re-examine this paper and support the excellent service that GPs provide. But I fear on this occasion, the damage has already been done.

Dr Mark Ironmonger is a GP in Brenchley, West Kent, and a board member of the Dispensing Doctors' Association

References

1 Avery T, Barber N, Ghaled M et al. Investigating the prevalence and causes of prescribing errors in general practice: The PRACTICE Study. GMC/University of Nottingham 2012. tinyurl.com/ckhbrgw

The study failed to say that most warfarin errors were at one practice



balneum CREAM
PLUS
Urea 5% and laurumacrogols 3%

ANTI-PRURITIC EMOLLIENT

Balneum Plus Cream Prescribing Information: Please refer to the Summary of Product Characteristics (SPC) for full prescribing information. Balneum Plus Cream contains laurumacrogols 3% w/w and urea 5% w/w. Uses: For the treatment of pruritus, eczema, dermatitis and eczema-like conditions where an emollient to soothe itching effect is needed. It may also be used for the continued care and relief following treatment of these skin diseases. Dosage and administration: Adults, the elderly and children: Apply to each affected area twice a day. The duration of treatment depends on the clinical response. Contraindications: Patients with known hypersensitivity to any of the ingredients. It should not be used to treat acute erythema, acute inflammation, burns or infected skin lesions. Spread

Warning and precautions for use: Use with caution if applied to broken or inflamed skin. Pregnancy and lactation: There are no specific restrictions concerning its use during pregnancy, but it is not to be used on the breasts or nipples or on the breast feeding baby's skin. Undesirable effects: Balneum Plus Cream has been used for skin care without serious side effects or the formation of pustules, aggravation of eczema or applied to the skin area. Contact allergy has also been reported. Package quantities: 100g tubes and 500g pump pack. Batch R150001: 100g 13.08.2009, 500g 14.08.2009. Legal category: SGL. Product licence number: PL 33016/01/01. Product Researcher: Almirall Farmaceutica, Schönbühlstrasse 3, Postfach 14200, D-40225, Hamburg, D-40225, Germany.

Date of preparation: January 2011. Further information is available from: Almirall, S.A., 4 The Square, Stoddley Park, Lutteridge, Leicestershire, LE17 1ET.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Almirall Ltd on 0800 00 87399.

Date of preparation: January 2011. J15210001.





**Blends proven efficacy¹
with fast-mix convenience**



For the treatment of chronic constipation

**MOVICOL[®]
LIQUID**

**macrogol 3350, sodium hydrogen carbonate,
sodium chloride, potassium chloride**

MOVICOL[®] Liquid, Orange Flavour, concentrate for oral solution. Abbreviated Prescribing Information. REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) BEFORE PRESCRIBING. **Presentation:** A clear, concentrated liquid, which is diluted in water to make an orange flavoured drink. Each 25 ml of MOVICOL Liquid is diluted in 100 ml of water before use and contains the following active ingredients: 13.125 g macrogol (polyethylene glycol) 3350, 178.5 mg sodium hydrogen carbonate, 350.7 mg sodium chloride and 46.6mg potassium chloride. **Uses:** Treatment of chronic constipation. **Dosage and administration:** Adults, adolescents and the elderly: 25 ml diluted in 100 ml of water 1-3 times daily in divided doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2 doses per day, each consisting of 25 ml diluted in 100 ml of water. Extended use may be necessary in patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medicine, in particular opioids and antimuscarinics. A course of MOVICOL Liquid treatment does not normally exceed 2 weeks, but can be repeated if required. Children (below 12 years): not recommended.

See MOVICOL Paediatric Plain. **Contra-Indications:** Intestinal perforation or obstruction due to structural or functional disorders of the gut wall, ileus and severe inflammatory conditions of the intestinal tract, such as Crohn's disease, ulcerative colitis and toxic megacolon. Hypersensitivity to the active substances or any of the excipients. **Warnings and precautions for use:** If patients develop any symptoms indicating shifts of fluids/electrolytes MOVICOL Liquid should be stopped immediately. MOVICOL Liquid contains 8.125 mmol of sodium in each diluted dose of 125 ml and should be considered when administered to patients on a controlled sodium diet. MOVICOL Liquid contains benzyl alcohol. Do not exceed the maximum recommended daily dose. **Interactions:** There is a possibility that the absorption of concomitantly administered medication could be transiently reduced. **Pregnancy and lactation:** There is insufficient data on use in pregnancy and lactation, and should only be used if considered essential. **Undesirable effects:** Reactions related to the gastrointestinal tract are the most common and include: abdominal pain, abdominal distension, nausea, dyspepsia, vomiting, diarrhoea, flatulence, borborygmi and anal discomfort. Allergic reactions, including anaphylactic reaction, angioedema, dyspnoea and

skin reactions can occur. Other effects can include electrolyte disturbances, headache and peripheral oedema. **Licensing and legal category:** Legal Category: P. **Cost:** 500ml £4.45. **MA number:** PL20011/0007. **For further information contact:** Norgine Pharmaceuticals Limited, Norgine House, Moorhall Road, Harefield, Middlesex UB9 6NS. Telephone: 01895 826606. E-mail: medinfo@norgine.com. MOVICOL[®] is a registered trademark of the NORGINE[®] group of companies. **Date of preparation/revision:** MD/2584/AUG/11.

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk>. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606.

Reference:
1. Attar A et al. Gut 1999; 44: 226-230.
MD/2852/MAR/12



www.MOVICOL.co.uk



Golf jibe is par for the course

From Dr John Derounian

Glenlivet,
Aberdeenshire

via pulsetoday.co.uk

Professor Malcolm Grant's jibe about GPs being 'out playing golf' is just based on the crass ignorance of an individual who clearly has the knowledge and insight of a cow pat (Commissioning board chair makes GPs 'playing golf' jibe, pulsetoday.co.uk/news).

Playing golf? If only I had time for such recreation. It's clear that the bureaucrats have no insight as to how pissed off we really are.

Like many other GPs I spend 55 hours minimum clinical contact with patients a week, and a further 20 hours on administrative work.

What more do people want? Phrases like 'flogging a dead horse' and 'getting blood out of a stone' spring to mind.

● From Dr San Sumathipala

Gloucester

via pulsetoday.co.uk

The professor, as far as I know, is not medically qualified. He appears to hold law degrees.

Whatever insight he has into GP work is limited by that

LETTER
OF THE
WEEK



Golf comment was a 'cheap jibe, made for easy laughs'

setback, and although he is entitled to his opinion, it does not do allow for an *ex cathedra* statement about the GP golf-player stereotype. I am sure he means well, but where is his evidence?

Surely, his august role chairing the NHS Commissioning Board must dictate that he chooses his words carefully?

The professor needs to venture into the GP community, and speak to us. We are available 8am to 6.30pm, give or take extended and out-of-hours work - unless, of course, he is too busy playing golf.

● From Dr Jonathan Harte

Nottingham

via pulsetoday.co.uk

Professor Grant is out of touch.

Till-timed jibes like his will do nothing to help healthcare providers collaborate to develop an NHS that works for patients as a whole, rather than being split into a series of individual commodities.

● From Dr Richard Page

Audley, Staffordshire

via pulsetoday.co.uk

I wish I had time to play golf! My clubs have been in the loft for 21 years (incidentally, the same length of time I have been out of hospital practice).

I know many more health service managers and hospital consultants than GPs that play golf, but I don't hear any jibes about them.

● From Dr Tom Inskip

Bedford

via pulsetoday.co.uk

I work five days a week as well as weekends and evenings for our local out-of-hours service, so my average working week is 55 hours long.

Playing golf less than once a week is my way of staying sane. Does Professor Grant want me to burn out even earlier?

His was a cheap jibe, made for easy laughs from an uninformed audience.

GPs should stand for election

From Dr Giles Wynne

North Hykeham, Lincolnshire

There will be doctors thinking about their duty to defend the NHS by standing as independents against coalition MPs at the next general election, and there are voters willing to support them.

The history of doctors standing in their locality is impressive, and even more so when standing on a single-issue campaign.

However, so shocking is the attack by the coalition on welfare benefits and pensioners that any campaign on the NHS would inevitably take on board these issues too.

There are constituencies where Labour expect to overturn an opposition majority, but other areas including my own in Sleaford and North Hykeham where the sitting Tory has a large majority.

He voted for the health bill without insisting on the publication of the NHS risk register first.

This is an MP who needs opposing, and if a GP was willing to stand there would be financial and physical support.

We must hit Government in the pocket

From Dr Jess Oldroyd

Blaydon, Newcastle

I agree entirely with Dr Malcolm Foulds who suggested that we stop being gatekeepers for a day ('Day of action will only create work', pulsetoday.co.uk/letters).

This would not irritate patients, but it would send a very strong message to the Government. No one ever gets to hear the real reason behind days of action and we will not get any sympathy if we adversely affect patient care.

If we have a financial impact it would be more difficult to ignore, especially if we grit our teeth and kept it going. It seems a hugely wasted opportunity that this was not the subject of the ballot rather than a day of reducing patient care.

For the record

Pulse's priority is accuracy. However, in the busy process of preparing a weekly publication, mistakes can occur. To draw our attention to an error, email letters@pulsetoday.co.uk

Apparently, judges give more to UK

From Dr Simon Ruffle

Twyford, Berkshire

Mr Cameron was questioned last week on why judges only pay 2% of their income to pensions. His reply was astonishing - he said it was in reflection for what they do for the country.

Every public-sector worker should be outraged, especially those of us who pay employers and employees pension payments of 21.5% and rising.

I think it may be time for all of us to withdraw from the Puzzi scheme we are effectively in and watch it collapse.

There is a solution that is Tory in the extreme. Freeze public-sector pensions and promised benefits tomorrow and hand over provision of pensions to one of their mate's financial companies to give us a pension on the same basis as the private sector.

I suspect judges would then want to pay more than 2%.

Ignorance doesn't listen to experience

From Dr Nicholas Ford

Croydon, south London

I have just had one of my most unpleasant experiences since becoming a GP in 1988.

An infrequent surgery attendee appeared on a booked 10-minute slot incandescent with rage. He perceived me to

be an uncaring, incompetent doctor who had failed to diagnose that his elderly, asthmatic mother was seriously ill with pneumonia, claiming that 'anybody could have known' and that her life had been put at risk.

The actual sequence of events was that a home visit had been made to assess severe neck pain and general malaise in a 78-year-old, asthmatic woman with two previous spinal operations and pneumonia in 1991, four days into a course of clarithromycin.

An assessment including vital signs, full examination and pulse oximetry was carried out, and after 20 minutes it was agreed this woman - who was speaking in full sentences and did not want to go to hospital - would remain at home under the care of her live-in daughter and be reviewed in the light of a pending chest X-ray result.

Advice was given to call again should there be vomiting, difficulty breathing or carer worry.

A script was issued for additional analgesia for the neck pain. Six hours later the daughter called out-of-hours, channelled through 111. The telephone triage flagged up possible 'crushing or severe aching/pain in the chest, upper back or upper abdomen' and an ambulance was despatched. The subsequent diagnosis was bi-basal pneumonia not apparent on chest X-ray but revealed on CT scan, in the face of persistent fever and very elevated CRP.

The son had no time for any explanation, either of the difference between an experienced GP's home visit

and a protocol-driven telephone triage service, nor of the fact that diseases evolve, and left grimly shaking his head.

He was not planning a formal complaint because of the ability of the medical establishment to close ranks and cover things up. Dr Roger Neighbour would have lamented lack of 'housekeeping' and that the remaining patients were kept waiting for over half an hour.

Where are applicants for new places?

From Dr Mary Hawking

Dunstable, Bedfordshire

via pulsetoday.co.uk

If the deaneries had to reduce training places by 7% because of a lack of 'quality applicants', how will increasing training places help ('Lansley agrees 20% rise in GP training places in radical workforce overhaul', pulsetoday.co.uk/news)? And is there any mention of extra funding?

My impression was that young GPs now find being a sessional GP more attractive than either a GP partnership or a salaried option.

If you are contemplating a career in medicine, who in their right senses would enter a branch where the future is uncertain? What is certain is that politicians of all parties are determined to denigrate GPs.

Does it matter how many training places are available if the job has been made so unattractive nobody wants to apply?

For Seasonal & Perennial Allergic Rhinitis

rhinolast

azelastine hydrochloride 0.1%

A fast acting nasal spray that delivers symptom relief within 15 minutes



Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Meda Pharmaceuticals Ltd.

Prescribers are recommended to consult the summary of product characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications. Legal category: POM. Further information is available from the Marketing Authorisation Holder: Meda Pharmaceuticals Ltd, Skyway House, Portonage Road, Tisbury, Wiltshire SP22 8PU.

MEDA

Pulse Plus

Our monthly CPD section provides an in-depth update on a clinical area, allowing you to earn credits for appraisal by answering questions online

Neurology

Key questions Multiple sclerosis

Neurologist **Professor Nikos Evangelou** answers questions from GP **Dr Melanie Wynne-Jones** on investigations, disease-modifying drugs, managing fatigue and diet

1 What are the common and less common presenting symptoms of multiple sclerosis? When should we refer?

The presenting symptoms of MS are notoriously variable. Some symptoms, such as tingling or fatigue, are seen daily in general practice in patients with no identifiable disease. So it is not surprising that patients often complain of delayed diagnosis. A third of newly presenting patients complain of weakness, and one in five report numbness or tingling. Some 20% also present with loss of vision because of optic neuritis. Sensory symptoms are often reported at the beginning of the disease. A common pattern is for tingling to start in part of a limb, and then – within a few days – spread to the whole limb.

Less common, but not infrequent, symptoms include vertigo, double vision and sometimes bladder symptoms accompanying leg tingling and numbness.

If you suspect a diagnosis of MS you should refer. Specifically, symptoms with discrete attacks lasting weeks or months are very suggestive of MS and should trigger a referral. Although it is uncommon to

initiate treatment after the first attack of MS, many patients report diagnostic delays and wish they had been diagnosed earlier.

2 As MS is said to be a clinical diagnosis, what investigations should be carried out?

In the right clinical scenario the diagnosis can be made without any tests – but I don't think that any patient will have been diagnosed recently without an MRI of the brain. MRI is non-invasive and in most cases of MS the scan shows white-matter lesions in a typical distribution. The lesions are usually periventricular, but can affect the brain stem and the cerebellum. Subcortical lesions are present in two-thirds of patients with MS, and the corpus callosum is also frequently affected.

Other diseases such as small vessel cerebral disease can cause white-matter lesions indistinguishable from MS lesions, but in these patients it is unusual for the spinal cord to be affected. So usually a combination of brain and cervical – or whole cord – MRI is requested in the initial evaluation.

In many cases a lumbar puncture is

In this issue


Neurology

Key questions **3 CPD hours**

Multiple sclerosis
page 18

Stroke management update

page 20



Urgent neurological problems

page 21

Five misconceptions in neurology

page 22

Ten top tips

Parkinson's disease

page 23

More online

Pulse Learning
▶ pulse-learning.co.uk

Hot topics in women's health **2 CPD hours**

A case-based learning module

Dermatology photo file: cryosurgery **1.5 CPD hours**

Our picture CPD module has been rated four stars




Optimising antibiotic management **1 CPD hour**

A sponsored video module

PulseToday
▶ pulsetoday.co.uk

Resource of the week

The European Association for the Study of the Liver have launched a smartphone app



Demyelination of nerve fibres can cause symptoms such as numbness and tingling

performed which looks for oligoclonal bands, and this is of great help when the diagnosis is in doubt. Evoked potentials are used less frequently, but the visual evoked potentials appear to be most helpful in identifying subclinical attacks of optic nerve involvement. Blood tests may exclude a systemic disease such as B12 deficiency, which can manifest with neurological symptoms.

PULSE Learning

3 CPD hours

The five articles that make up this PulsePlus CPD module, worth 3 credits, will be available free to all members of Pulse Learning until 13 June 2012

▶ pulse-learning.co.uk

3 Should GPs manage relapses by prescribing oral steroids or by referral for specialist care?

Sometimes it is difficult to diagnose a relapse – many MS symptoms will recur in the context of an infection, excessive tiredness or stress. These 'pseudo relapses' should not be treated with steroids. But a patient who experiences many relapses is likely to require escalation of treatment. It can be difficult to draw the line between what is a significant disabling relapse and what is a mild sensory attack, so all relapses should be discussed with, or referred to, the MS team. No patient with MS should be on long-term oral steroids. The MS team won't treat all relapses with steroids, and if they do decide to use steroids, an explanation of the risks and benefits of these in the context of an acute relapse will be given.

4 Depression is common in patients with MS, and fatigue and pain can also be debilitating. What can GPs suggest?

Depression, fatigue and pain can be extremely debilitating, and the lack of visible manifestations means that their

importance may not be appreciated.

GPs know better than anyone how depression can cause fatigue. Identifying and treating depression is one of the most effective steps we can take to reduce MS fatigue. The general principles of the use of antidepressants apply to patients with MS. But I would bear in mind that sedation can worsen fatigue caused by MS. It is a fine balance between treating depression in MS – which is very common – and not causing too many side-effects.

Tricyclics with their anticholinergic action at a low dose can help patients with bladder symptoms and are also very helpful in treating pain. Fluoxetine has been shown to reduce fatigue, even in non-depressed patients. Amitriptyline and fluoxetine have also been shown in small studies to reduce the uncontrollable laughing and crying (pseudobulbar symptoms) that we occasionally see in MS patients.

Poor sleep because of leg spasms can also cause terrible fatigue. Treating sleep difficulties is very important and it is worth asking about night pain, cramps and anxiety. Often 10-20mg of baclofen or 300-600mg of gabapentin before bed can reduce the pain and spasms without any side-effects. Review medication frequently, as many drugs can cause fatigue.

Amantadine 200mg daily has shown a benefit in some patients with fatigue in a small study, so when all else fails it is worth trialling a patient on this for a month or two. Musculoskeletal pain will benefit from exercise, physiotherapy and NSAIDs. And neuropathic pain often responds to

gabapentin, pregabalin and tricyclics.

Opiates have a role to play in MS, especially for exacerbations of pain. But given their side-effects and cost, it is best to follow local guidelines on use of opiates in treating non-cancer pain. Sometimes it is necessary to get the input of the local pain team.

5 When and how would you use disease-modifying drugs? Are there any new medications in the pipeline?

Not all patients with MS benefit from disease-modifying drugs – they are only useful in the early inflammatory, relapsing-remitting stage of the disease.¹ Unfortunately, our current drugs are of no benefit in progressive disease.

The current recommendations² advise using disease-modifying drugs when patients have experienced at least two relapses causing significant disability over two years. Interferons and glatiramer are injections given at home. These drugs are partially effective and reduce the risk of relapses by a third. If the disease is more active, natalizumab – a monthly hospital infusion – can be initiated after consideration of risks and benefits. A new oral drug, fingolimod, has become available in the UK in the last few weeks for patients with the most active MS. This is the first oral MS drug, but it is aimed at more aggressive MS not controlled with first-line treatments. A couple more oral drugs are expected to become available in the coming years. More powerful drugs given in hospital are at the stage of being assessed by the authorities.

6 Do you recommend dietary modification or supplements?

Diet plays an important role in many diseases, and since we do not know what causes MS, it is understandable that many have suggested diet could be a key factor. The evidence for this is thin, but playing an active role in diet selection and exercising is important in helping patients to take control of their disease.

I promote healthy eating and encourage patients to keep an eye on their weight, because overweight patients with MS experience more walking difficulties.

There is some evidence from trials in animals that eating fish may protect against demyelination,³ and as fish is a part of a healthy diet, I suggest to patients with MS who like fish that they could probably eat more.

Vitamin D supplementation has not been proven conclusively to reduce relapses or to have an impact on disability, but the evidence is getting stronger all the time.⁴ So I mention to patients that I would take vitamin D if I had MS – though not all MS neurologists would do the same. The 'MS-specific' diets which are currently in vogue have not been tested, can be restrictive and include lots of supplementation, so I do not recommend them.

7 How should we advise a woman with MS who wishes to become pregnant?

Having MS should not stop a patient having a baby – MS does not affect fertility and pregnancy does not have a long-term effect on the progression of MS – but there

are important issues to consider. I would review all medications and make sure the patient balances the potential risks and benefits during pregnancy. At this stage, I would ask the patient to get in touch with her MS team because the decision to discontinue treatments is not straightforward – especially if patients are on disease-modifying drugs.

Fatigue and any help needed after delivery are important issues to consider. If a parent has MS, there is also a small increased risk of the child getting MS – the general population risk is one in 800 and that increases to one in 50 when a parent has MS. Although this is considered an acceptable risk by most, it is important to discuss it with any patient with MS who wants to become a parent.

Professor Nikos Evangelou is a clinical associate professor of neurology at Nottingham University Hospital

Dr Melanie Wynne-Jones is a GP trainer in Stockport, Cheshire

References

- 1 Wolinsky J, Narasana P, O'Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicentre, double-blind, placebo-controlled trial. *Ann Neurol* 2007;61:94-24.
- 2 Association of British Neurologists. Revised Association of British Neurologists' guidelines for prescribing in multiple sclerosis. 2009. [theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_Final\(1\).pdf](http://theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_Final(1).pdf)
- 3 Torbidsen O, Brunborg LA, Thorsen F et al. Effects of dietary intervention on MRI activity, de- and remyelination in the cupressine model for demyelination. *Experimental Neurology* 2009; 215:160-6
- 4 Munger K, Zhang S, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology* 2004;62:60-5

Cardiovascular Women's health Now with Ear Nose and video and picture modules, Pulse Learning Gastroenterology is the Diabetes Commissioning one-stop shop Repository for all your Cardiovascular Dermatology CPD needs. Allergy pulse-learning.co.uk Mental health Pain relief Ophthalmology

PULSE Learning



"Easy to follow, good practical advice rather than full of guidelines"
Dr Nicholas Buckley

Join today at pulse-learning.co.uk

Annual premium membership only £49.95 + vat

Update on stroke management

Dr Geoff Cloud, consultant stroke physician, gives an update on stroke management in primary care

CHADS2 remains the first choice for assessing stroke risk in atrial fibrillation.

The CHADS2 is a clinical prediction tool to assess the risk of stroke in patients with atrial fibrillation. It uses the presence or absence of five factors – congestive heart failure (scores 1), hypertension (1), age 75 years or greater (1), diabetes (1) and prior stroke/TIA (2) – to produce a score of 0 to 6. It has been thoroughly validated and corresponds to a range of annual stroke risk from 1.9% for a score of 0 to 18.2% for a score of 6.

Anyone who scores more than 1 should be considered for anticoagulation. This tool is simple, has universal validation and is widely used.

You can download a version of CHADS2 from pulselearning.co.uk/tools-and-resources.

Recently, a modified version – CHA2DS2-VASc – has been developed which includes additional risk factors including vascular disease. It has been added as an option in the 2010 European Society of Cardiology guidelines for the management of AF. But as CHADS2 is the score used in the QOF AF indicators for 2012/13, this is likely to be the score used most widely in general practice.

NICE changes guidance on secondary prevention after a stroke.

The optimum antithrombotic regime for secondary prevention of stroke is either aspirin 75mg OD in combination with dipyridamole MR 200mg BD or alternatively clopidogrel 75mg OD. On the basis of ease of compliance and cost – since clopidogrel has now come off patent – most stroke physicians are currently recommending clopidogrel.

Very occasionally we would use aspirin and clopidogrel in combination – for instance, in patients with symptomatic intracranial stenosis – but we wouldn't advocate doing this long term because of the increased bleeding risk.

The NICE guidance is not helpful here because it distinguishes between TIA and stroke¹ and recommends they be treated differently. Dipyridamole MR plus aspirin is still recommended first line for people who have had a TIA. The guidance says no recommendations are made about the use of clopidogrel after a TIA because it is not licensed for this indication. But as the causes of TIA and stroke are exactly the same, it seems odd to treat them differently.

Stroke units reduce mortality and length of stay.

Randomised controlled trials demonstrated the benefit of stroke units over general medical care over 20 years ago. This has been shown to be the case in clinical practice in the NHS in the National Sentinel Stroke Audit, which since 1998 has demonstrated that as access to specialist stroke units has increased, mortality and morbidity due to stroke have reduced.

The most recent report has shown that 30-day mortality has reduced from 20% in 2008 to 17% in 2010.² Stroke units also

reduce the length of time patients spend in secondary care – patients admitted to a stroke unit within four hours have a median length of stay of nine days compared with 12 days for those who were not directly admitted to a stroke unit.

Every acute hospital in Britain has a stroke unit, and patients who have a stroke in 2012 should expect to be treated in one, rather than in a general medical or geriatric ward.

The Stroke Improvement National Audit Programme publishes results on key indicators of acute care and reviews local services, so you may find it useful to look at this – particularly if there are several providers close by, so that you can decide which to refer your patients to.³

Thrombolysis after acute stroke can only be given by a specialist.

Any patient with ischaemic stroke should be given thrombolysis within four and a half hours of symptom onset if their clinical symptoms are not improving, and as long as they do not have any contraindications to thrombolysis. The licence has recently changed from three hours to four and a half hours, following a study of the efficacy and safety of this.⁴


Although there have been studies suggesting suitably trained paramedics can safely administer thrombolysis to patients with an acute myocardial infarction, the situation with stroke is far more complex. It is crucial that the patient has a CT scan to exclude a brain haemorrhage before thrombolysis is given, and this is why thrombolysis is currently not given before the patient's arrival at hospital.

Throughout the NHS, patients should have access to thrombolysis 24 hours per day. This may be in the local hospital or by a networked approach of one hospital among a group providing a 24/7 stroke thrombolysis service for a region. The important issue here is that patients do not have excessive delays to access specialist opinion and brain imaging.

The clinician administering the thrombolysis should be trained in stroke clinical decision making and using thrombolysis – for example, a neurologist or stroke physician. The British Association of Stroke Physicians has a training scheme and there are now deanery subspecialty training programmes in stroke available for trainees in parent specialties such as neurology, and acute and geriatric medicine.⁵

Carotid surgery is only necessary in patients with symptoms of carotid stenosis.

People with symptoms of acute non-disabling stroke or TIA who have a relevant carotid stenosis of 70% or more should have carotid surgery within two weeks of symptom onset. There is some evidence that carotid surgery may be beneficial for patients with symptomatic stenosis from 50% to 69%. The absolute benefit in such patients, however, seems only to be present



Patients must have a CT scan to exclude haemorrhage before thrombolysis is given

if they are operated on within two weeks of symptom onset. A randomised controlled trial this year will look at randomising such cases between best medical treatment and surgery.

There are very few indications for carotid surgery in patients with asymptomatic carotid artery stenosis – the risks and costs of surgery generally outweigh any benefit.

Dabigatran is a new option for patients having difficulties with warfarin.

In AF, anticoagulants are far better at preventing recurrent stroke than anything else. Dabigatran has good randomised controlled trial data and this has all been looked at by NICE.

For secondary stroke prevention, dabigatran can be considered in people who have difficulty keeping within the therapeutic INR range, or those who are at increased risk of bleeding complications on warfarin.

There is often reluctance in primary care to anticoagulate patients, but all patients with ischaemic stroke in AF should be considered for anticoagulation and a clear reason should be documented where a decision is made not to treat.

Warfarin is economically a good choice, but the new oral anticoagulant agents will have an increasing role to play, I am sure, as they come off patent. The total of 39% of patients with AF on warfarin after stroke in the 2010 National Sentinel Stroke Audit is some way short of the 60% aspiration set by the Department of Health.

Lowering blood pressure is key in reducing risk of recurrent stroke.

Patients who have had ischaemic strokes caused by AF should be prescribed anticoagulants. Otherwise antiplatelet treatment should be instigated as described above. These patients should also be considered for statins – aiming to reduce total cholesterol below 4mmol/l and LDL cholesterol below 2mmol/l.

There is a strong association between lowering blood pressure and reducing the risk of recurrent stroke. I would suggest trying to lower blood pressure to 130/80mmHg or less as a target, but however much it is lowered there will be a relative reduction in the risk of recurrent stroke.

Giving patients the usual advice about lifestyle modifications is also very important – for example, stopping smoking, moderating alcohol intake and exercising.

Patients with a stroke due to brain haemorrhage should be followed up to look for an underlying structural reason for the haemorrhage. For example, MRI may pick up tumours and some arterio-venous malformations.

Overall, the key to secondary prevention after haemorrhagic stroke is lowering blood pressure. There is no strong evidence for lipid lowering after haemorrhagic stroke compared with ischaemic stroke.

I would usually avoid anticoagulants or antiplatelets because of the risk of recurrent haemorrhage in such patients.

Dr Geoff Cloud is a consultant stroke physician, honorary senior lecturer in the department of clinical neurosciences at St George's Hospital, London, and associate director for the Royal College of Physicians' stroke programme

This May has been Action on Stroke month, and the Stroke Association has launched its Life After Stroke campaign to challenge the barriers that prevent stroke survivors from making their best possible recovery. To find out more visit stroke.org.uk/campaigns.

References

- 1 NICE. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events TA210. NICE October 2010
- 2 National Sentinel Stroke Clinical Audit 2010: Public Report for England, Wales and Northern Ireland. May 2011
- 3 Royal College of Physicians. The stroke improvement national audit programme public comprehensive report. March 2012
- 4 Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase three to four and a half hours after acute ischaemic stroke. *NEJM* 2008;359:1317-29
- 5 British Association of Stroke Physicians. baasp.ac.uk/home.aspx. (accessed 8 May 2012)

Further reading

- Department of Health. *National stroke strategy*. 2007

Consultants **Dr Chris Taylor** and **Mr George Samandouras** advise on how to identify and manage urgent neurological and neurosurgical problems

TIA and ischaemic stroke

A transient ischaemic attack is a transient episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischaemia, without infarction.¹ Ischaemic stroke involves evidence of infarction and is a major cause of morbidity and mortality.

The annual UK incidence of ischaemic stroke is 1.5-2 per 1,000. Risk factors include old age, hypertension, obesity, TIAs, diabetes, high cholesterol, cigarette smoking and atrial fibrillation.

The risk of stroke during the first seven days after a TIA can be predicted from the ABCD2 scoring system:

- A: age – older than 60 years (scores 1)
- B: raised blood pressure – systolic blood pressure greater than 140mmHg or diastolic blood pressure greater than or equal to 90mmHg (1)
- C: clinical features – unilateral weakness (2) or slurred speech (1)
- D: duration in minutes – at least 60 minutes (2), 10-59 minutes (1) or less than 10 minutes (0)
- D: presence of diabetes (1).

Patients should be referred immediately if they have:

- two or more TIAs in a week
- TIA while on warfarin
- an ABCD2 score of more than 4.

Everyone else should be referred for urgent outpatient assessment.

Ischaemic stroke may require aggressive management of haemodynamic instability with adequate fluid resuscitation and inotropes, ensuring end-organ perfusion.

Thrombolysis with tissue-type plasminogen activator should be given intravenously within four and a half hours, or intra-arterially within six hours, of symptom onset. Patients with large, non-dominant hemisphere infarction and raised intracranial pressure may benefit from decompressive craniectomy.

Secondary prevention involves anticoagulation for non-valvular atrial fibrillation, antihypertensives and antiplatelets – aspirin and dipyridamole or clopidogrel started 24 hours after thrombolysis can reduce stroke recurrence by 25%.

Exacerbations of multiple sclerosis

The prevalence of multiple sclerosis is 50-90 per 100,000 in the UK, and around 80% of patients have the relapsing-remitting form of the disease.

Relapses or exacerbations are episodes of focal neurological disturbance lasting more than 24 hours, without an alternative explanation, and with a preceding period of clinical stability lasting at least 30 days.

Management is focused on aggressively treating severe exacerbations, in order to shorten the duration and intensity of neurological dysfunction.

Urgent discussion with, or referral to, a neurologist is recommended – a short course of high-dose steroids (methyl prednisolone) orally or intravenously

as advised may be helpful.

Adrenocorticotrophic hormone is an alternative in patients unable to cope with the side-effects of steroids.

All patients with relapsing-remitting MS should begin one of the disease-modifying therapies – an interferon, glatiramer acetate or natalizumab/retuximab.

Guillain-Barré syndrome

Guillain-Barré syndrome is an acute inflammatory polyneuropathy. The annual incidence is one in 100,000 in the UK population.

It affects more men than women, and is most common between ages 15 to 35 and 50 to 70 years.

Guillain-Barré syndrome is usually preceded by an infective illness such as a URI or gastroenteritis. It can also follow a vaccination or a new drug, or can be triggered by chronic illness or infection such as lymphoma or HIV.

The classic presentation is paraesthesia, progressive (less than four weeks) ascending neuropathic weakness of more than one limb and areflexia, and it is often associated with autonomic dysfunction and neuropathic pain.

It may involve the cranial nerves, causing swallowing problems and respiratory muscle failure.

Diagnosis is based on clinical features, neurophysiological studies and examination of cerebral spinal fluid. All patients require urgent hospital admission and monitoring until the disease has reached a plateau.

Specific treatment consists of high-dose intravenous immunoglobulin or plasma exchange. Mortality is between 5-10%, but 85% of patients make a full recovery within one year.

Status epilepticus

Recent guidelines⁴ define status epilepticus as five minutes or more of continuous clinical or electrographic seizure activity, or

recurrent seizure activity without recovery between seizures.

Status epilepticus has an annual incidence of 25 per 100,000 in the UK population. It affects men and women equally, and in a third of cases it is the first presentation of epilepsy. Emergency assessment of the airway and cardiopulmonary function may be necessary. Oxygen may be needed and potential causes – including hypoglycaemia, alcohol withdrawal, toxins, CNS infections and brain injury – should be treated.

Status epilepticus requires urgent transfer to A&E for drug therapy.

In early status epilepticus, use buccal midazolam as an 'out-of-hospital' option.

Mortality is high, at 20%, and depends on the patient's age, duration of seizure and underlying cause.

Subarachnoid haemorrhage

Subarachnoid haemorrhage, the acute release of blood in the subarachnoid space, usually results from a ruptured intracranial aneurysm. In post-mortems, one in 20 people are found to have intracranial aneurysms, but the incidence of subarachnoid haemorrhage is only 10.5 per 100,000 people per year.

The clinical hallmark of subarachnoid haemorrhage is sudden onset of very severe headache – often described by patients as the worst of their life. Half of patients have a period of unresponsiveness and a third of patients have focal signs.

Subarachnoid haemorrhage is often misdiagnosed as migraine, influenza, viral syndrome, arrhythmia or syncope, especially in patients who are fully conscious and have no focal deficits.

Any patient suspected of having a subarachnoid haemorrhage should be immediately referred to the local hospital for a non-enhanced CT scan, and if this is normal, a lumbar puncture.

On confirmation of a subarachnoid haemorrhage, the patient should be

urgently referred to a neurosurgical unit for a catheter angiogram and endovascular coiling of the identified aneurysm.

In the UK, more than 90% of aneurysms are coiled and the remaining are clipped surgically.

Brain tumours

More than 100 types of brain tumour have been described by the World Health Organisation. Symptoms and signs depend on the location of the tumour and the rate of its growth:

- The presence of any mass within the confines of the skull produces headache and, rarely, nausea and projectile vomiting.
- Irritation of the cortex can produce seizures, common in meningiomas growing in the convexity of the brain or low-grade gliomas of the temporal lobe.
- Tumours growing near to, or at, the sensorimotor or language cortex produce weakness, sensory deficits and expressive or receptive dysphasia.
- Some tumours produce visual symptoms or endocrine abnormalities – the classic example is pituitary tumours.

The diagnosis of a brain tumour can be difficult in patients presenting with headaches only. Such cases should be discussed – preferably – with neurology or neurosurgery on-call teams. Patients with focal neurological deficits, confusion or seizures should be referred urgently to A&E for a brain scan and onward referral to a neurosurgical unit. In contrast with other types of tumours, the terms 'benign' and 'malignant' do not apply as literally in the brain. A slow-growing and histologically benign tumour can have devastating effects if it grows in an area such as the brain stem or the sensorimotor or language cortex.

The most common intrinsic brain tumour is the glioblastoma – a malignant astrocytoma, arising from the astrocytes – which occurs at a frequency of three to four new cases every 100,000 population every year.



Degenerative disc disease can cause spinal cord compression

Urgent neurological problems

21 The standard treatment is aggressive surgical resection followed by radiotherapy and chemotherapy.

Spinal cord compression

Spinal cord compression can be catastrophic if not recognised and treated urgently.

Patients often present with established deficits such as weakness or paralysis with or without bladder and bowel symptoms. Any patient who presents with new onset of weakness of legs, or arms and legs, should be presumed to have spinal cord compression until proven otherwise.

Patients often have myelopathic signs – brisk reflexes, increased tone, up-going plantars and positive Babinski sign.

Patients suspected of having spinal cord compression should be referred urgently to their local hospital or to a neurosurgical unit for an MRI scan of the spine.

The sooner the spine is decompressed and stabilised – ideally within 24 hours – the higher the chances of preserving remaining function and occasionally reversing established deficits.

By far the most common cause of spinal cord compression is metastatic tumours to the spine (80-90%), followed by intradural spinal tumours such as meningiomas, neurofibromas, and schwannomas, trauma, haematomas, abscesses and degenerative disc disease such as large prolapsed cervical or thoracic disc disease.

Dr Chris Taylor is a consultant in neuroanaesthesia and neurocritical care and **Mr George Samandouras** is a consultant neurosurgeon at the National Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Trust

Dr Chris Taylor trained at University College London Hospitals. He is an examiner at the Royal College of Anaesthetists and his clinical interests include neurocritical care, anaesthesia for myasthenia gravis, functional neurosurgery and neurosurgical procedures.

Mr George Samandouras (georgesamandouras@gmail.com) was trained in Oxford and completed a fellowship in Paris. He is editor of the best-selling book *The neurosurgeon's handbook*. His clinical interests include advanced techniques for the surgery of brain tumours, minimally invasive surgery and spinal surgery.

References

- 1 Easton JD, Saver JL, Albers GW et al. American Heart Association/American Stroke Association scientific statement: definition and evaluation of transient ischaemic attack stroke. 2009; 40: 227-33.
- 2 Brophy GM, Bell R, Claassen J et al. Guidelines for the evaluation and management of status epilepticus. *Neurocrit Care* 2012, online 24 April (accessed 11 May 12)

Further reading

- Samandouras G (editor). *The neurosurgeon's handbook*. Oxford University Press, 2010

PULSE Learning

Our most popular CPD modules over the past week

- Avoiding the pitfalls in the new 2012/13 QOF 1 CPD hour
- Key questions 1.5 CPD hours
PAD
- Key questions 1.5 CPD hours
Allergic rhinitis
- Clinical casebook 1.5 CPD hours
Infertility
- Occupational medicine 1 CPD hour
Low back pain

► pulse-learning.co.uk

Five misconceptions in neurology

GP and epilepsy specialist **Dr Jane Williamson** on five common misconceptions

1 Headache is a useful predictor of a brain tumour
Patients who present in primary care with a headache often have one of three possibilities in mind: they need glasses, they have high blood pressure or they have a brain tumour.

GPs see a lot of headache, but do a great job in managing it themselves – only 3% of patients are referred to secondary care for further assessment.¹ It's true that headache is a very common symptom of brain tumour – 70% of patients will experience a headache during their illness at some time. But the risk of headache being associated with a brain tumour is very low and is estimated to be around 0.09%.²

It is easy to understand how an overzealous or inexperienced GP might want to err on the side of caution, especially as some of the non-headache symptoms of brain tumour are subtle.

The latest guidance from the Department of Health on direct access to diagnostic tests for cancer recognises that selecting patients for investigation of a possible brain tumour is particularly dependent on a GP's experience and intuition.³ The criteria for urgent referral for suspected brain or CNS cancer are clearly set out in a document available to download at pulselearning.co.uk/downloads.

And finally – headache rarely warrants an immediate referral, but the exception is a sudden-onset headache which is maximal immediately or within a few minutes and lasts longer than an hour, which should ring alarm bells of a subarachnoid haemorrhage.

2 Anyone who's had an episode of unexplained loss of consciousness should be referred to a neurologist

In our fast-track epilepsy clinic, only about 50% of referrals actually have epilepsy. Most of the rest are faints or vasovagal attacks. There are a few with other physical problems, such as cardiac dysrhythmia. And about a fifth of those referred have psychogenic pseudoseizures of one kind or another – what we used to call pseudofits, but are now termed non-epileptic attack disorder (NEAD).

The best way to decide who to refer to neurology is to take a careful history, both from the individual and also from any reliable witness to the episodes.

Witnesses can often give a pretty good description of a classic seizure, and if the patient recalls having some sort of aura-like experience before the episode it's clear they had a seizure.

Feeling light-headed with a sound of drumming in the ears is usually a sign of a vasovagal attack, especially if there's a witness description along the lines of 'he went pale and then sort of crumpled'.

Features that are common in NEAD but rarer in epilepsy include: biting the tongue, seizures lasting more than two minutes, seizures having a gradual onset, a fluctuating course of disease severity, the eyes being closed during a seizure and side-to-side head movements.



As with all somatoform disorders, it is important to recognise it as early as possible – and hopefully before the patient starts taking antiepileptic drugs.

3 Self-referred brain scans are pointless, but harmless

What should we tell patients who insist they need a brain MRI and are willing to pay around £250 to go private? Should we tell them to go ahead as it won't do any harm?

The answer is probably 'no' – for a couple of reasons.

There's a one in 37 chance of finding an abnormality that may well never bother the patient.

A UK meta-analysis looked at the number of incidental findings in 19,559 asymptomatic people who underwent MRI brain scans. These were defined as apparently asymptomatic intracranial abnormalities that were clinically significant because of their potential to cause symptoms.

They found a 2.7% prevalence and a number needed to scan of one in 37.⁴ The major dilemma – and this affects asymptomatic volunteers who undergo a brain MRI as part of a research study – is whether to treat incidental brain findings and, if so, how.

In fact, most of the abnormalities were meningiomas, which grow slowly and remain asymptomatic, and surgery on this type of tumour comes with a significant risk of morbidity.

Similarly, aneurysms affect about 2-3% of the population, but treating an aneurysm invasively carries a 5-10% risk of stroke-related death.

References

- 1 Lattinck R. Headache and migraine in primary care: consultation, prescription and referral rates in a large population. *J Neurol Neurosurg Psychiatry* 2006; 77: 185-7
- 2 Kerrick D, Ahmed F, Bahia A et al. Imaging patients with suspected brain tumour: guidance for primary care. *Br J Gen Pract* 2008; 58: 280-5
- 3 Department of Health. Direct access to diagnostic tests for cancer: best practice national pathways for general practitioners. April 2012. dh.gov.uk
- 4 Morris Z, Whittaker WN, Longworth WT Jr et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2009; 339: b3016

The second problem with brain scans is the the detection of incidental findings carries implications for some patients' driving licences, life insurance policies or even their jobs.

So – rather than being relieved to get a nagging patient off our backs – we should stick to the principle of *primum non nocere* and refuse to lend any credibility to a pointless and potentially harmful private enterprise.

4 Cervical radiculopathy is caused by a trapped nerve

Nerves do not simply get trapped and untrapped and this certainly is not the case in cervical radiculopathy – neck pain that radiates into the arm.

This is generally caused by irritation of the lower cervical roots (usually C5-T1) from a herniated disc or degenerative disc disease.

While surgical decompression provides rapid and substantive relief, it is not without complications and the long-term outcomes are unclear.

Degenerative cervical radiculopathy with a subacute onset generally settles, and a wait-and-see policy is recommended for the first six weeks. Patients should be referred if symptoms persist after this.

A recent study published in the *BMJ* explored whether using immobilisation with a semi-hard collar or physiotherapy could improve symptoms faster than a simple wait-and-see strategy.⁵

Pain improved substantially in both the physiotherapy and immobilisation groups compared with those assigned to the wait-and-see approach, making the simpler option – collar and relative rest – the most preferable.

You can learn more about cervical radiculopathy – including the red flags – in the Hot topics in musculoskeletal medicine CPD module at pulse-learning.co.uk.

5 Parkinson's disease with dementia and dementia with Lewy bodies are different diseases

It's quite common for patients who have had Parkinson's disease for some time to be referred to psychiatry because they have started to become forgetful and even experience hallucinations – with Lewy body dementia as the chief suspect.

In fact, both conditions are two presentations of a single underlying disease process – Lewy body disease – which these patients have probably had for some time.

Other than age of onset and possibly response to levodopa, there are no major differences between dementia with Lewy bodies and Parkinson's disease, and the management aims are essentially the same – to treat motor, cognitive, psychiatric and autonomic dysfunction using the same drugs and non-pharmacological strategies.

There are revised diagnostic criteria for dementia with Lewy bodies and for dementia in Parkinson's disease, and neurologists should be using an agreed terminology, which would certainly help patients understand what is happening to them.⁶

Dr Jane Williamson is a GP in Birmingham and associate specialist in epilepsy

- 5 Kugler B, Tans JTJ, Boeken A et al. Cervical collar or physiotherapy versus wait-and-see policy for recent-onset cervical radiculopathy: randomised trial. *BMJ* 2009; 339: b3883
- 6 McKeith I. Dementia with Lewy bodies and Parkinson's disease with dementia: what are two worlds colliding. *Front Neurosci* 2007; 7: 374-82

Ten top tips Parkinson's disease

Dr Alistair Church, GP and associate specialist in neurology, offers his tips on managing patients with Parkinson's disease

1

Patients don't always present with a tremor.

Up to 20% of patients, particularly those with early-onset disease, never develop a tremor. For a diagnosis of Parkinson's disease the patient must have bradykinesia. A good way of identifying this is to ask the patient to tap their thumb and first fingers together as fast, and with as big an amplitude, as they can. Watching a patient walk down the corridor can also be helpful – reduced arm swing on one side can be an early sign.

2

Consider Parkinson's in younger patients.

With a prevalence of one in 500 and an annual incidence of one in 8,000, the average GP looks after three or four patients with Parkinson's at any time.¹ The mean age of onset is 60, but 15% of patients present before the age of 45. Younger patients often present with stiffness, slowness or dystonia rather than tremor.

3

Non-motor symptoms can be an early sign.

Parkinson's causes non-motor problems which can predate the motor symptoms, sometimes by years. Loss of sense of smell and thrashing about when asleep – 'living out their dreams' – can be early signs. These are non-dopamine-related complications, so do not respond to dopamine replacement therapy.

4

Be aware of sleep problems.

Patients with Parkinson's can find it difficult to sleep because of restless legs, painful 'off medication' dystonia and urinary frequency. Periodic limb movements may also disturb their partner – this may respond to a low dose of clonazepam. Daytime somnolence can result, and may be compounded by dopamine agonists.

5

Audit patients on dopamine-depleting drugs.

Antipsychotics and some anti-emetics deplete dopamine, so think carefully before putting patients on these long term. A good practice audit would be to review all patients on repeat prescription of these, before symptoms start – because drug withdrawal once extrapyramidal problems have emerged doesn't always lead to resolution.

6


Think again if there are atypical features.

Diagnosing atypical Parkinsonism can be challenging. Features such as a rapid time course, early falls, difficulty swallowing, early autonomic features, ataxia, marked early cognitive impairment and eye movement disorders may suggest an alternative diagnosis, such as progressive supranuclear palsy, multiple-system atrophy or corticobasal degeneration. If patients do not respond to dopamine replacement therapy, review the diagnosis – and if the issues persist, refer.

7

Treatment should be started when the patient becomes functionally disabled.

Medical treatment should be started when patients become functionally disabled or they are unable to perform tasks that are important to them.



9

Adjunctive treatments may help.

Other treatments for the motor complications of Parkinson's include catechol-O-methyltransferase inhibitors – such as entacapone or tolcapone – which increase the bioavailability of levodopa and prolong its effects. These must be taken with each levodopa dose. Monoamine-oxidase type-B inhibitors prevent dopamine breakdown at the synapse. They can be used as a monotherapy or as adjunctives and have a once-daily dosing regimen, but should not be used in patients on SSRIs as this could induce a serotonergic crisis. Amantadine has minor benefits for motor symptoms, but is mainly used to reduce dyskinesia. It can cause hallucinations and confusion.

10

Get early input from other specialists.

Parkinson's nurse specialists are often the key to co-ordinating care and managing motor complications. Physiotherapists and occupational therapists can be invaluable in improving a patient's confidence in managing their symptoms. A speech and language therapist can enhance the volume and intelligibility of speech, and in the later stages of Parkinson's swallowing assessment can be important.

Dr Alistair Church is a GP and associate specialist in neurology, with a special interest in Parkinson's disease, in Newport, south Wales

Parkinson's UK offers support to all healthcare professionals working with people with the condition. For information, resources or to join the charity's professionals' network, visit parkinsons.org.uk/professionals.

References

¹ Ben-Shlomo Y. The epidemiology of Parkinson's disease. *BMJ* 1997;315:655-68

GP Locums, know your tax as you go and make the most of your money.

Early mornings, late nights, on-the-go. It can be hard to sit and organise your finances. But, a surprise tax bill can be a bitter pill to swallow.

For over 16 years Brookson have provided specialist accounting services to the medical profession. With a strong compliance heritage, dedicated support six days a week and innovative technology – we've put an end to guesswork and unexpected tax bills.

Our all-inclusive package means:

- Your tax position is updated daily.
- Your accounts are updated daily.
- You won't miss a payment or deadline.
- Free tax planning advice.
- Plus, access to Specialist Advisors*, six days a week.

And so much more...

Cure one of your headaches and call Brookson for a FREE Financial Health Check...

Our Specialist Advisors are 'on-call' now

0800 1105 966

or visit www.brookson.co.uk

Not just your everyday accountant |

B brookson
Freedom to earn

*Excludes weekends and bank/public holidays. | Specialist Advisors available six days a week, Monday to Friday, 9am-6pm and Saturday, 9am-3pm.

Pulse Business & Commissioning

Practice Business In this issue

Avoiding data breaches How to share data or release personal information without falling foul of the rules ► page 24



More online

Practice dilemma What should you do if one of your nurses is injured at work?

► pulsetoday.co.uk/practice-dilemma

How we reduced DNAs by a third – for free A no-cost way to reduce the risk of wasted appointments

► pulsetoday.co.uk/practice-business

pulsetoday.co.uk/practice

Commissioning In this issue

Using volunteers to deliver healthcare

► page 26



More online

Commissioning dilemma Can you commission a service without going to tender or using AQP?

► pulsetoday.co.uk/commissioning-dilemma

What we know so far An update on the NHS Commissioning Board

► pulsetoday.co.uk/tools-and-resources

pulsetoday.co.uk/commissioning

Nine ways to avoid costly data breaches

GPs will face increasing demands to share data – so it is essential to understand the regulations.

Dawn Monaghan

from the Information Commissioner's Office explains

Data protection is likely to become a hot topic as GPs enter the new world of clinical commissioning. Under CCGs, GPs are likely to be sharing more of their patient and other data with many other organisations – both within and outside the NHS.


Priorities for GPs are:

- to make sure they fully understand their obligations under the Data Protection Act and Freedom of Information Act
- to put practical systems in place to ensure they can meet those obligations.

GPs need to be sure that they fully understand that they can share data, but must identify the risks associated with that sharing and mitigate them. The following nine points will help GPs ensure practice data is protected and that they understand what information can and can't be shared.

1 Beware of information breaches

Activities that can risk data breaches include putting data onto memory sticks or sending data to work from home without using a secure network or encryption process. If any data is downloaded to a mobile device, it should be



encrypted. There is guidance on the Information Commissioner's Office (ICO) website about suitable encryption packages. There are a number of different commercial options available and data controllers should ensure they meet the current standard, such as the recommended FIPS 140-2 (cryptographic modules, software and hardware) and FIPS – 197.

If GPs are working from home or sending information to somebody else, they should always use NHS.net and send data on a secure connection. This doesn't always happen, particularly in small organisations where people may send data to their hotmail account, for example.

We also see a lot of breaches involving faxes. Our guidance is not to use a fax machine as a secure means of transferring

data. If you have no other option, there must be stringent policies in place and staff must be trained in how to use the policies – for example, staff should ring the recipient and make sure someone will be at the machine to collect it immediately, double-check the fax is being sent to the right number and ring back after the fax has been sent to make sure it has arrived.

There is also the issue of staff unlawfully accessing or using data. This is usually because of incompetence rather than for malicious reasons. Staff must be made aware that they only have access to data for certain purposes and are not allowed to use it in any other way.

Another common data breach is when someone – for example, a private detective – will pretend to be someone's relative to blag

information over the phone. Practices could use security passwords or questions to ask enquirers before providing them with personal data.

2 Remember that the GP holds responsibility for the data

GPs have obligations under the Data Protection Act, but staff at the ICO often find they pass on their responsibility to the practice manager too readily. A GP is able to delegate the tasks, but not the responsibility – if something happens to data held by the practice, the GP is seen as the 'controller' of that data regardless of their involvement or otherwise with a breach.

GPs should make sure the people they are delegating to are fully aware of what the obligations are and how they must deliver them. It is also important that the person delegated to makes the GP aware of:

- how the data is being managed
- whether security measures are working
- what data monitoring systems are in place
- what agreements cover sharing arrangements if data is being shared.

GPs and their staff are already very aware of issues of confidentiality. What often needs more consideration is how data is stored, who has access, how it is shared and awareness of what GPs' responsibilities are.

3 Report data incidents

When you've had a breach – such as losing a memory stick with personal data on that you know is not encrypted – it's worthwhile reporting it. The ICO can help in ensuring the right questions are asked, such as: what was the data on the memory stick, was it encrypted and what has the GP done about it? We can make an assessment and recommend what systems to put in place to make sure it doesn't happen again. Practices can then handle the matter themselves with our support and assistance, which will cover the practice and the GP's reputation.

4 Put systems in place to avoid future breaches

You should know what personal data is held and how it is stored. Establish where the risks are and identify weak points in security measures. Monitor staff awareness of security and consider setting up a group to discuss 'what if?' issues. Data security is a role for the information governance lead rather than the information technology lead – although in general practice, the practice manager may cover both roles. It is not just to do with technical aspects – the data controller should have technical, such as encryption, and organisational measures in place. Most of the breaches we see are to do with human error, not technology.

5 Tailor training for your staff

It is important to tailor training to the needs of your staff. There is no point in sending staff to a conference on data protection to be subjected to a day of legalese. Staff need practical training in areas such as: what do GPs need to do? What is the role and responsibility of the practice manager? What is everyone else's role and to what level do they need training? GPs should contact the information governance manager at their PCT or CCG for advice about good local courses.

The Department of Health's *Information governance* online training toolkit is a good place to start to raise awareness when you have a new member of staff, or staff who have never been trained in data protection. However, beware of using it as a tickbox exercise – don't assume your staff are trained because they have done the toolkit.

6 Be clear about handling data access requests

There are currently two means of requesting access to information. Personal data can be accessed by the individual in question through the Data Protection Act, via a subject access request. If a practice receives a subject access request in writing, the data must be provided to the individual making the request within 40 days. Practices can charge a fee, but be careful that all the data the practice holds on them is provided – not just the patient's medical records, but also items such as emails or letters.

The Freedom of Information Act covers access to official, rather than personal, information – for instance, if someone asked the practice to provide them with their policy on chaperoning. If a patient wants information provided to the practice about themselves, that is more complicated. It might slip out of data covered under the Freedom of Information Act into data protection, as there might be personal information involved. There might also be third-party data that might be exempt.

If a patient is requesting their own personal data it needs to be provided, and if it's official information it needs to be provided unless it is exempt – for instance, if disclosure would be likely to prejudice a criminal investigation or someone's commercial interests. There is a list of exemptions on the ICO website.

7 Understand the regulations about data sharing

Data requests from sources such as the police, social services or the CCG can be complex. They are data sharing, rather than a request for information. Data sharing means the disclosure of data from one organisation or more to a third-party organisation or organisations, or the sharing of data between different parts of an organisation. Each situation is very

dependent upon the circumstances.

A data controller cannot share information unless certain criteria are met. In the case of sensitive personal data, it must meet one of the criteria in both schedule 1 and 2 of the Data Protection Act (which cover areas such as whether the person the data relates to has consented to it being shared, how the data was obtained, how long it is kept, whether it is being transferred outside the European Economic Area and whether processing is necessary to protect the individual's 'vital interests'). If you get explicit consent from an individual to share their data with someone else that would be compliant, but often that is not practical or possible.

It is incumbent on the data controller to decide whether or not they share the data based on whether they think they have the grounds to do so. Information on data sharing can be found in the data sharing code at tinyurl.com/3fn5hj4. This includes a checklist covering such questions as whether sharing is justified, whether you have the power to share, key points to consider and recording your decision.

Specific legislation covers data sharing

with certain organisations – the police, for instance, can obtain a court order to access information.

8 Check your marketing policies are ICO-compliant

Marketing communications fall under the *Privacy and electronic communications regulations*, which are stringent rules on what practices can and can't market to people. The key point to bear in mind is: what did you collect the data for in the first place? Would those people expect to receive information relating to that?

A patient knows their GP is collecting their data for the purposes of healthcare, so if the practice was marketing a Well Woman clinic to them that should be perfectly safe.

But if the practice were to share a patient's contact details with a company selling smoking patches, it could be in trouble as the information wasn't collected for that purpose.

9 Don't let information governance hold your practice back

GPs often think they can't do something that involves sharing data

because of data protection legislation.

But not sharing data can be just as dangerous as sharing it – GPs just need to be confident that they are familiar with what can and cannot be done. It should be treated as any other business process. Ask yourself: what am I doing and why? What are the risks? Can I mitigate them?

Dawn Monaghan is the group manager for public services at the Information Commissioner's Office

MORE ONLINE

The ICO website

Offers guidance on obligations of data controllers, the *Data sharing code* and a template for a privacy impact assessment for your practice.

► ico.gov.uk

Connecting for Health

Has a guide to meeting obligations on data protection, as well as training materials for practice staff.

► connectingforhealth.nhs.uk/systemsandservices/infogov



Livial®

tirolone

A confident choice in managing the menopause

Treatment of oestrogen deficiency symptoms in postmenopausal women

Full prescribing information is available on request.
Consult the Summary of Product Characteristics for further information before prescribing, particularly in relation to side effects, precautions, and contraindications.

POM
© Gender registered trademark of Menck Sharp & Doherty Corp., a subsidiary of Menck & Co., Inc., Whitehouse Station, NJ, USA.
© Menck Sharp & Doherty Limited 2011. All rights reserved.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events with this product should also be reported to MSD Drug Safety Department on 020 6971777/352773.

Menck Sharp & Doherty Limited, Hertford Road, Harefield, Herts, UK AL9 5AB (UK1168)
Date of preparation - September 2011
Expiry date - September 2013
UK1168 270013d

MSD

Using volunteers to deliver healthcare

Volunteers can provide a low-cost source of labour for health schemes – and the act of volunteering has benefits too. Three GP commissioners give their own experiences

Volunteering has long been a staple of the social care and charity sectors, but GPs have traditionally hesitated before using unpaid workers. Many would argue that there is little opportunity for patients to contribute to primary care because they lack a clinical background, but GPs are beginning to find

opportunities to involve patients more in local healthcare services. The obvious benefit to GP commissioners is the low cost, but volunteer schemes can still be challenging to set up and time consuming to run given the low or non-existent levels of clinical skill among most volunteers.



Dr Michael Dixon



Dr Sam Everington

Here, three GPs give their advice on how to use volunteers safely and effectively.

Volunteer counselling

Dr Michael Dixon *Cullompton, Devon*

At my practice, we employ volunteers according to their background. At the

more experienced end, we have two counsellors with a community background – a former health visitor and primary school teacher. At the less experienced end, we have a gardener's group and a fundraising team. All the volunteers are overseen by our health facilitator Ruth Tucker, who is employed part-time by the practice.

We also offer patient groups for those with long-term conditions such as fibromyalgia and diabetes.

Social isolation can be a big problem, so to try to overcome this we have a café facility, which the gardeners' group produces vegetables for. The gardener's group also offers herbal remedies as alternatives to prescriptions where we GPs consider it appropriate.

Our costs are minimal, and there is even a cost benefit for schemes like our borrow-a-book service, where a per-book charge of £1 has added up to enough for us to buy an ECG.

We have had to pay for Criminal Records Bureau checks for our counsellors, but while there's no direct saving, having them

working with our practice has taken the pressure off child and adult mental health referrals by providing an opportunity for low-cost early interventions. The counsellors pay for their own insurance.

A project at our practice to promote gentle exercise in 2009 used volunteered activities such

as walking, gardening and 'exercise on prescription', and found that participants managed to lose weight, stop blood pressure medicines and relieve depression symptoms.

We saw a small reduction in the number of clinical appointments booked in the six months following the intervention, especially among high-demand patients.

We've found the greatest cost of having volunteers is employing a health facilitator, but the role ensures that we have well-organised patient groups, good training and strong links to the wider local volunteering scene.

Volunteering as therapy

Dr Sam Everington *Bromley by Bow, east London*

The Bromley by Bow Centre (BBBC) has been offering people in a deprived area of east London support on their health, education and employment for over 20 years. My practice, the St Andrew's Centre, is located on site and offers support to the health centre based on four key aims – supporting

Knock out Staph...

...and soothe itchy eczema

Introducing new Dermol Wash

- Established and well proven formulation
- Two antiseptics provide significant antimicrobial activity against MRSA and FRSA (methicillin and fusidic acid-resistant *Staphylococcus aureus*)
- Two emollients which soothe and rehydrate dry skin, helping to restore the correct skin barrier
- Pump dispenser, ideal for use at the sink

When your patients with dry itchy eczema need an antimicrobial emollient wash

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Dermal.

Dermol® Wash

Benzalkonium chloride, chlorhexidine dihydrochloride, liquid paraffin, isopropyl myristate.

Use: Antimicrobial emollient for use as a soap substitute in dry and pruritic skin conditions. Please refer to SPC for full details before prescribing, particularly in relation to side-effects, precautions and contra-indications. Further information is available from Dermal Laboratories, Telford Place, Gosmore, Hitchin, Herts, SG4 7DR. (H)



Dermol Wash



Dr Amit Bhargava

patients' education, creativity, employment and environment.

The BBBC accepts 3,500 referrals a year from the borough of Tower Hamlets. Dan Hopewell, director of strategies at the BBBC, estimates GPs at my practice make 20 to 30 referrals to them a month, often taking the patient from their GP consultation straight to the office of the person in the BBBC the patient is being referred to.

Many of our referrals send patients to the Time Bank scheme, where they are asked to assess their skills and needs and to join a skills exchange programme.

Rather than recruiting volunteers to work with patients, patients are often 'treated' by registering as volunteers. The

scheme currently has around 100 members with 50-60% engagement in volunteering activities.

The BBBC also offers health projects for specific patient groups, such as Pollen – a horticulture therapy group for patients with mental health issues. Funding comes from outside the BBBC for this scheme, which has been specially commended by the charity Mind.

Vulnerable adults can attend a day centre at the BBBC, and we target patients for whom English is a second language through early intervention and cancer screening outreach among local students.

Queen Mary University is currently in discussions with the BBBC to develop a programme for volunteer and work experience medical students to work as health navigators in the reception area of our practice and the BBBC, and to pursue follow-ups after appointments.

The health navigators will then assess the patient's condition, recommend a good self-care programme and put them in touch with support groups where appropriate – for instance, for weight loss or diabetes.

The two main opportunities I see in volunteer schemes are encouraging patients to take more responsibility for their own health, and the big wins available through better lifestyle.

Many of the things GP commissioners aim to target – areas of health spend such as emergency admissions and disease areas such as diabetes – can be dramatically improved by giving patients better resources for dealing with their health

problems and by changing their diet and exercise habits.

Volunteer schemes can be a good, low-cost way for us to reduce our workload by delegating healthcare back to patients.

The cost to the practice is hard to assess, but one of my partners dedicates one to two days a week to help manage the BBBC's activities. The integration extends both ways, with the chief executive of the BBBC working as a non-profit-sharing partner of our practice.

Carer support networks

Dr Amit Bhargava *Crowley*

Volunteer services make a strong contribution to our practice brand and help us maintain our rate of list growth – currently sitting at 85 to 100 new patient registrations a month. Neighbouring practices that offer similar volunteer-run services are also experiencing a comparable level of list development.

The main strategy for our volunteer schemes is to make them self-sustaining, so they create a zero-cost clinical benefit to GPs without requiring time or financial input from us.

We started with offering a general support network for carers, but as it grew we established more specific groups – for example, for Alzheimer's disease and back pain.

Initially we offered simple social meetings for carers in the networks, but we now provide health education sessions too.

We employ a co-ordinator for our volunteer schemes who works 12 hours a

week, but managing the volunteer schemes is only part of her role and the groups mostly organise themselves.

The practice makes no financial input to volunteer groups and, as it doesn't charge rent even to private health providers using rooms on the site, there is no loss of income from providing volunteer-run groups with a place to meet.

Some successful programmes we participate in were suggested by our carer groups. So for example, we encourage people to use the 'This is me' scheme run by the Alzheimer's Society, in which patients or their carers fill in a questionnaire with photo ID, describing the patient and their health needs and medicines, and providing contact details for their main carer. It has been shown to help reduce the average length of hospital stay for participants.

We also have an armchair exercise group for the frail elderly, which is provided and run by the local branch of Age UK.

Early intervention is the main objective of our volunteer services, and our 8% reduction in unscheduled admissions since last year can be partly attributed to their introduction.

Since we introduced our volunteer services, demand for GP appointments and requests for home visits have also gone down.

MORE ONLINE
Go to pulsetoday.co.uk/tools-and-resources to download a copy of the 'This is me' form developed by the Alzheimer's Society for patients with dementia

PULSE Medical Store

Providing you with the widest range of medical goods & services

Powered by



1 Schuco Molemate 2.0

Used with the supplied MoleMate software, this device allows the clinician to make informed judgments on suspect lesions quickly and accurately. The live on-screen image ensures that patients can be shown the view and clear, concise reports can be produced.

A case study of the Schuco Molemate has proved the following:

Commercial Results – £7,600 in referral costs saved in the first year – (based on a cost per referral of £200)

- 76% reduction in the two-week wait dermatology referral rate
- 27% reduction in referral rate to dermatology clinics overall
- No missed diagnoses (false negatives) revealed to date

Now £3,598.80 Includes VAT
Save £7,600 on referral costs Code PWS173



Save
£7,600 on
referral
costs

2 Keeler Jazz Pocket LED Otoscope

The Jazz Otoscope from Keeler combines portability with performance. The lightweight design is backed up with bright xenon illumination and long lasting rechargeable batteries.

Features:

- 3 interchangeable colour rings
- Fibre Optic Otoscope
- Brilliant Xenon illumination
- 3 x magnification

Buying more than 1!
call for a quote - bulk deals available

Now £90.00 Includes VAT
Was £102.00 Code PW4235



12%
OFF

All Jazz Instruments are supplied with 3 interchangeable colour rings

3 Merlin Medical M-Pulse Lite Pulse Oximeter

This value for money product is reliable and easy to operate, making it an excellent choice for performing on-the-spot SpO₂ and Pulse Rate measurements.

Features:

- Universal finger clip - suitable for adults, children, and neonatal patients
- SpO₂ Range: 70 - 99%
- SpO₂ Accuracy: 80 - 99%, ± 2%; 70-79%, ± 3%
- Pulse Rate Range: 30 - 235bpm
- Pulse Rate Accuracy: ± 2% or 2bpm
- Dimensions: 58mm x 32mm x 34mm
- Requires 2x AAA batteries (supplied)
- FREE carry case

Now £45.54 Includes VAT
Was £59.94 Code PW32538



24%
OFF
FREE Case
W6421

May Special - At least 10% off all orders!

Stethoscopes, ABPM's, Otoscopes and lots more - Quote 'May Special' when ordering

How to order

Call **0800 212 855** E-mail **sales@pulsemmedicalstore.co.uk**

Online **www.pulsemmedicalstore.co.uk** (To find more products and offers)

**Order now
Free delivery
on orders
over £100**

Advertised deals cannot be used in conjunction with any other promotions unless otherwise agreed. Offers valid for 4 weeks.

Contact

Cliff Brown
Advertisement executive
020 7332 2924
For a quote send adverts to:
clifford.brown@briefingmedia.com

Rates

£18.00 - £26.00 per single column
centimetre.
Colour rates available on request

Issue date/Copy deadline

Publication date Wednesday.
Booking deadline Thursday 4pm
preceding publication date.
Copy deadline Friday noon
preceding publication date

By post

Briefing Media
3rd Floor, Mermaid House
Puddle Dock
London, EC4V 3DB

Website

pulsetoday.co.uk

DOCTORS/GPs REQUIRED



College Health is a dynamic and innovative organisation; our ethos is putting patients first and delivering high quality locally based primary care services. We have been successful in being awarded primary care contracts in the Medway Towns and Essex.

We are seeking highly motivated, enthusiastic individuals who value working as part of a multi-disciplinary team and are committed to providing high quality clinical services which changes health outcomes for the better.

We have vacancies for 1 full time GP and a part time maternity cover Locum. We are a unique practice in that we have a registered patient list and also a busy walk in centre.

It is an exciting time to join as the centre is expanding its services in line with current commissioning intentions to provide more services within primary care.

We already have consultant led clinics in Cardiology (echo) and ultrasound and outreach clinics coming soon in dermatology, pain management and diabetes.

If you are interested in working in an exciting, progressive environment why not consider us?

Applicants should contact the Practice Manager,
Anne Osbaldeston by email at anneosbaldeston@nhs.uk
or by calling 01375 889702.

Informal enquiries welcome



GP Partnership Opportunity

The Practice is looking for an enthusiastic, highly motivated GP to join our friendly rural dispensing practice in the beautiful Vale of Belvoir. The practice has five thousand patients is fully computerised and scores highly in QOF and patient surveys. The vacancy is for a full time and part time General Practitioner.

- Emis clinical system moving to System One
- PMS practice
- Leicester Medical School Training Practice
- No OOH commitment
- Good Schools within the local area

For more information or to arrange an informal visit
Contact Lisa Wild Practice Manager

Please apply in writing with your CV by 29th June 2012

Main surgery:
The Welby Practice
Walford Close
Bottesford
Nottinghamshire
NG13 0AN

Direct line to Practice Manager 01949 845366
Email: lisa.wild@pct.nhs.uk

Salaried GP required

with a view to Partnership

Full time (8 sessions) or part-time considered



Werrington Village Surgery is a GMS Practice supporting c7879 patients, located in a modern purpose built surgery. We are a semi-rural practice, close to the Peak District, in an area with reasonably priced housing.

- 4 Progressive Partners (3.25 WTE)
- Active in Practice Based Commissioning
- High achiever of QOF points
- Excellent support team with low staff turnover
- Fully computerised Emis LV Practice (soon to be EMIS Web)
- Strong Nurse team; triage
- Strong Community support with integrated teams
- No requirement for out of hours cover

Apply in writing enclosing C.V. to
Peter Bailey, Practice Manager
Werrington Village Surgery
Ash Bank Road, Werrington
Stoke-on-Trent, ST9 0JS
peter.bailey@northstaffs.nhs.uk

Telephone for informal discussion or visit, 01782 304742
Closing date 22.6.2012 Interviews 12.7.2012

Staunton Group Practice, Wood Green,
London N22 8HE

Maternity Locum

required for approx seven sessions per week,
starting a.s.a.p

Come and join a well established, modern GMS inner city training practice with seven partners and three salaried GPs serving a diverse population with a list size of 16,500 patients. We are a dynamic, friendly, primary care team providing a wide range of high quality health care to our practice population.

- High QoF Scores
- Under/Postgraduate training
- Attractive, purpose-built premises
- Paperlight using InPS Vision

Candidates preferring a shorter period or fewer sessions should still apply as we can be flexible. Pay and terms negotiable.

If you are interested, please send a CV with a covering letter (by email only) to: **Sanjiv Gupta, Practice Manager**, email: staunton.group@nhs.net

For informal enquiries: 020 8826 1991



SALARIED GP / PARTNER FULLTIME

The Partners are seeking an enthusiastic, motivated GP to join our well established, hard working and friendly team in the Royal Harbour town of Ramsgate, Kent.

- Four doctor GMS/INCON practice; supportive nursing and admin team.
- Together we manage 7000 patients, emphasising clinical excellence and continuity of care.
- Committed to achieving high standards in QoF, delivering Enhanced Services and actively engaging in local commissioning.
- Planning stages for re-development of premises with the addition of a new 100 hour Pharmacy.

The successful candidate would be committed to the provision of quality care and the onward development of the practice.

Partnership would be considered after a successful mutual assessment period.

Closing date Friday 6th July 2012

Informal enquiries and visits welcome.

Please e-mail CV and letter of application Richard Lawson,
Practice Manager richardlawson@nhs.net

THE SCOTT PRACTICE G P PARTNER

Large, innovative, advanced training practice in Doncaster, easy access to transport links (just 30 minutes from Sheffield). We are looking to appoint a new GP Partner for 7 sessions a week, to join our existing team from December 2012.

- 13,600 patients
- ISO9001 premiere (moving to Synergy)
- 9 Gp partners + Managing Partner
- Advanced training practice - 5 Registrars
- Medical students
- High QOF achievement
- Branch surgery
- 6 month period of mutual assessment as salaried GP

If you have high clinical standards, high commitment to General Practice, are motivated and flexible then you will fit in well.

If you feel this is you please send your CV with covering letter to:
Mrs Rose Fells, Managing Partner, The Scott Practice,
1 Greenfield Lane, Balby, Doncaster DN4 0TG

Closing date for applications 25.6.12

Please note interviews will be held on Saturday 30th June only.

Waterloo - Merseyside Partner Vacancy - due to retirement

We are looking for a GP partner to join our well organised, established, friendly small practice.

- List size 3200
- Emis Web
- GMS
- Excellent QOF achievement
- 7 sessions per week

We have a happy, efficient and supportive team and have very good links with the wider PHCT. We strive to provide the highest standards of modern primary care while maintaining the very best of traditional family general practice.

Apply in writing with covering letter, CV and two referees to
Dr Duran, 20 Kingsway, Waterloo, Merseyside, L22 4RQ
Tel 0151 920 9000

Closing date for applications 16th June 2012.

We are seeking an enthusiastic salaried GP for 4 or 5 sessions per week Tuesday to Friday. We are a PMS Practice with 10,000 patients in Crowborough East Sussex.

A GP with an area of Special Interest and the flexibility to provide additional sessions as cover would be an advantage.

Please send a CV and covering letter to Frank Powell,
Practice Manager, Beacon Surgery, Beacon Road,
Crowborough, East Sussex TN6 1AH.

Dr Mughal and Dr Bhatti Partners are looking for a salaried GP for 6 sessions.

Wages negotiable. High QOF achievement and friendly environment.

Contact Shirley Suker by e-mail
shirley.suker@nhs.net or tel 0208 550 3740



End of Life Nutrition

Band 6 • £25,528 - £34,189
37.5 hours per week • 2 year fixed term contract

Are you an experienced nutrition support dietician looking for a challenge? This is an exciting new Macmillan sponsored post for a minimum of 2 years. You will join an existing Band 7 working as part of a Specialist MDT. This will be a varied post with cover of a hospital in-patient/day hospice facility, together with community cover. There will also be scope for research, education sessions and audit.

You will need to bring knowledge, show empathy and commitment in this sensitive area. In return you will be well supported by the organisation, wider Birmingham Community Team and Macmillan.

For informal enquiries please contact
Sue Mackie - Clinical Specialist Dietician
on 0121 465 2002.

Closing date: 29 June 2012.



John Taylor
Hospice

DOCTORS/GPs REQUIRED

Full/Part time GP Required

Dallam Lane Medical Centre is looking for 1 full time or 2 part-time Salaried GP's with a view to partnership for the right person(s). We are offering a competitive package with the opportunity for professional development.

Dallam Lane Medical Centre is a well established, family orientated practice which has recently moved to new and modern premises in the busy town centre, with significant growth potential.

The practice is a high QOF achiever and prides itself in the high standard of clinical care provided to our list of 3,500 patients. The practice is EMIS PCS moving to EMIS web.

Please apply in writing to Angela Bonney, Practice Manager, Dallam Lane Medical Centre, Warrington, Cheshire, WA2 7NG. Tel: 01925 572 334 or email warr-pet.dlmc@nhs.net. For further information please call Angela Bonney on 07811 768103.

Does your Practice currently include a Pharmacy?

Do you receive an annual rent from the Pharmacy?

If the answer to both these questions is 'Yes' then you might be able to sell the space that the pharmacy occupies for at least 10 times the current annual rental and in some cases even more than that. This means that the current Practice Partners can share in the value of the pharmacy premises now and unlock a sizeable amount of value.

For an informal discussion on your best options please email Conor Daly of Rushport Advisory LLP at conor.daly@rushport.co.uk

Full Time GP
(probable future partnership)

Large forward-thinking practice seeks full time GP due to retirement.

Our ambition is to achieve, by an effective team approach, the highest quality of progressive family health care, in a happy and compassionate environment.

We care for 16,100 patients in the pleasant Weald of Kent area. We operate four buildings, two of which are purpose-built Medical Centres. We are part dispensing and currently have 3 GP Trainers. We have an excellent nursing, ancillary and PHC team.

Please write with full CV to Peter Nicholas, Managing Partner, Hildenborough & Tonbridge Medical Group, Westwood, Tonbridge Road, Hildenborough, Kent, TN11 9HL.

Closing date extended to 8th June 2012

Shortlisted candidates will be welcome to arrange an informal visit to the practice.

Foxhill Medical Centre, North Sheffield
Tel: 0114 2854 313

PART TIME PARTNER (salaried GP considered)
REQUIRED FROM SEPTEMBER 2012
5-7 sessions (negotiable)

We are a friendly, innovative practice with a reputation for providing good patient care, having major links with the local community and being a strong, supportive team that values a good sense of humour. Well established partnership with opportunities for teaching/mentoring.

- LIFT premises under construction • No buy in
- Six partners (4.5 WTE) • Highly skilled nurses
- Committed PHC • 6,100 patients • Training practice
- Involved in PBC • High QOF achievers
- Complementary therapies (acupuncture, herbalism, massage)
- Practice Psychotherapist
- Many DESs including Substance Misuse.

Please contact Dr Amanda Romano
or email mandyromano@nhs.net

Closing Date: Thursday 5 July 2012, at 12 noon

FULL OR PART TIME DOCTORS REQUIRED
FOR BRITISH CRUISE SHIP COMPANY

LOCATION - CRUISES SAIL WORLDWIDE
RECRUITER - NOT SPECIFIED
SALARY - NOT SPECIFIED

We are looking to recruit experienced Doctors to work onboard Cruise Ships. You will be working as part of a friendly and dedicated team of experienced nurses. Amongst the many benefits, you are entitled to bring your spouse/partner to sail free of charge.

Please email applications to: info@cyg-net.co.uk

Doctors required UK-Wide
for Insurance medicals.

dc life

...is growing. Join our panel of doctors who provide Insurance Medicals.

- Adhoc or sessional work • Training provided
 - Excellent remuneration • Full administrative support
- This is a unique opportunity to be part of our team. If you are interested please send a copy of your CV to:

info@dc-life.co.uk Tel: 0845 140 3000

Tudor House and Rectory Road Medical Practice

GP LOCUM NEEDED

2-4 Sessions all day Tuesday and some Thursdays
Starting ASAP

Required for large friendly medical practice in Wokingham town centre

- 11 partners and 1 salaried doctor with 22,500 patients
- Full clinical team including triage nurse, nurse led clinics and HCA
- EMIS-UK moving to EMIS web in July 2012
- See our website for more details www.tudorhouseurgery.co.uk

Please apply by email with a copy of your CV and covering letter to:
tudor.house@nhs.net

Permanent and sessional roles in **sjb medical**

Cambridge, Ipswich, Leicester and Lincoln
Positions also available across UK including Northern Ireland

£54,600 + excellent benefits package

Full time, part time and sessional roles available.

Due to expanding requirements, our client is seeking full time, part time and sessional GMC registered Doctors. These roles require at least three years of broad based experience, excellent communication and IT skills with full time training provided prior to starting.

Our client provides functional assessment services on behalf of the UK government.

Flexible opportunities for experienced Doctors are also available, from a minimum of 5 sessions per week to fit around current work commitments.

To get started email your CV and covering letter to:
jobs@sjbmedical.com or call 020 7832 1961

fb.com/sjbmedical

@sjbmedicaldocs

BIRCHINGTON MEDICAL CENTRE
FULL TIME PARTNER (8 Sessions) REQUIRED
DUE TO RETIREMENT

We are a progressive team of 7 GPs (5.5 FTE), 4 nurses, and excellent administrative staff. We are committed to upholding and continuously improving an excellent standard of patient care. We operate from attractive purpose built premises overlooking farmland and located in a seaside village.

- Paperless Emis LV (moving to EMIS web)
- High QOF achievement
- In house cardiology GPwST Clinic
- Active in local commissioning group which expects early authorization
- Teaching practice
- Local attractions include sailing, water sports, and championship golf courses.
- 45 minutes from channel tunnel

Application and CV to Mrs Sarah Price, Birchington Medical Centre, Minnis Road, Birchington CT7 9 HQ or Sarah.price@nhs.net
Telephone: 01843 848818

SALARIED GP

ROTHSCHILD HOUSE SURGERY, TRING, HERTFORDSHIRE
(From October 2012)

We are GMS practice seeking a permanent salaried GP to join our friendly team.

- Ideally 8 sessions a week working over 5 days however we would consider less for the right candidate
- Large semi-rural dispensing practice on the edge of the Chiltern Hills
- Purpose-built premises in attractive market town
- Well organised management, clinical and administrative teams
- Paper-light practice, IMPS 'Vision' clinical software.
- Teaching practice
- Excellent local schools. Easy access to London, motorway and rail networks

CVs will be accepted in support of an application form. For an application pack please contact:

Dorothy Pluck on 01442 892465 or Jenny Stevens on 01442 892466
Email: dorothypluck@nhs.net or jennystevens@nhs.net

Closing date 22nd June 2012



MSc Medical Humanities

www.kcl.ac.uk/prospectus/graduate/medical-humanities

This adventurous and interdisciplinary programme examines the relationship between the humanities, science and medicine, and how humanistic principles operate in healthcare and clinical practice.

The Centre for the Humanities & Health at King's College London is a Wellcome Trust-funded research centre in the medical humanities, involving academics drawn from departments of English, History, Philosophy, Film Studies, the School of Nursing, and the Institute of Psychiatry. Bursaries are available for the best applicants.

Distinguish yourself

Partnership Vacancy – September 2012

Llys Meddyg, Sway Road, Morriston SA6 6JA
Tel: 01792 771392.

We are hoping to attract you to join our team – preferably as a full time Partner but negotiable for the right candidate!

Percentage Share Premises Purchase Option
Well established Isaf Gwynedd Practice
Excellent Support Team
8 weeks Annual Leave

Informal enquiries welcome.

Written applications together with your CV to Mrs Ceri Jenkins, Practice Manager at the above address or by e-mail to ceri.jenkins@gp-w98029.wales.nhs.uk

Closing Date: 22th June 2012

Sunnybank Heath Centre, Blackwood, Gwent.

PART-TIME SALARIED GP
Sessions negotiable

We require a part-time GP to work in a friendly Practice

- 4,700 patients
- High QOF achievements
- Vision clinical system, paperlight practice.
- Purpose built premise
- 2 Full-time partners

Please email to meryl.dumas@gp-w9914.wales.nhs.uk with your CV by the 30th June 2012.

BEDFORD

Two Full Time SALARIED GP's

For friendly training APMS Practice (11,200 pts) and Nurse led NHS Walk in Centre, ideally to start as soon as possible. Salary negotiable.

Please contact: Sam Paul, Practice Manager, Pattee Medical & NHS Walk in Centre. Tel: 01234 314990. Email: sam.paul@nhs.net

COURSES
College of Medicine and Veterinary Medicine
Flexible online courses in
Global Health


Keep up to date with the global health agenda by studying for short, credit-bearing postgraduate modules in Epidemiology for Health Professionals or Evidence Based Medicine, or for a Certificate, Diploma or Masters in Global Health: Non-Communicable Diseases. Study in your own time through our interactive virtual learning environment. Apply now for September 2012.

tinyurl.com/global-health-professional-dev

OVERSEAS
Work in Australia

As a GP in Australia you can...



Escape the NHS reforms

Earn over £200,000 a year

Have a lifestyle second to none

Have more time for friends and family

Enjoy great housing

Benefit from a booming economy

Contact us today and we will help you every step of the way.

Call: 01279 677000 Email: gp@dwsmedics.com

DWS Medics

Providing medical professionals to Australia



It's a long flight to New Zealand, but a short walk to the beach.

You could be a GP anywhere in the world. Be one here, in Gisborne New Zealand.

Three Rivers Medical needs general practitioners. Visit www.3rivers.co.nz to start your adventure on our edge of the earth.


Full or Part-time Salaried GPs

To join Church Close Surgery, Madeley, Telford, which is a small friendly practice of approx 4700 patients. We are seeking 2 or more salaried GPs to cover between 12 - 14 sessions per week, some starting in Aug-Sept this year and more next April 2013. We are happy to consider job share or any other proposals. BMA Contract and salary scales.

We are EMIS paper lite, and the surgery has an excellent established telephone triage system in place. We run chronic disease clinics led by nurses, and achieve high QOF points. We will hopefully be moving to new practice premises in the next 18 months or so.

Successful applicants will practice evidence based medicine and prescribe cost-effectively, and be flexible in their role to meet the needs of the surgery. Minor op skills or willingness to train is desirable.

All informal enquiries to Julie Ellis (Nurse Partner/Managing Partner) 01952 586616 or apply in writing with CV to Julie Ellis, Church Close Surgery, Church Close, Madeley, Telford. TF7 5BP.
julie.ellis1@nhs.net

Closing date End June 2012.

LOCUM AGENCIES

Locum Staffing

Finding work doesn't have to be time consuming. Let the work come to you.

- Earn up to £100 p/hour
- Placements nationwide
- Newly qualified/experienced welcome
- Free e-mail and sms job alerts
- Excellent referral bonuses

Ongoing locum and salaried positions throughout the UK

We are providers of GPs to:

- PCTs
- Hospitals
- GP Practices
- Walk in Centres
- HM Prisons
- Out of Hours Services
- Medico - Legal

t. 08450 562 867 | f. 01582 345 355
info@locumstaffing.co.uk | www.locumstaffing.co.uk

R LOCUMS

Find locum jobs online



- ✓ Set your own rate
- ✓ Flexible work
- ✓ Cut out the middle man

Now recruiting across UK

www.rlocums.com

dr-locums

Earn £1000* per day

Recruiting across the UK :-

London * Sussex * Essex * Suffolk * Midlands * North England * Wales

Walk In Centres

Out of Hours

Prisons (RCGP1 trained)

GP surgeries

Call 020 7498 7999

www.drlocums.com

gp@drlocums.com

COURSES & CONFERENCES

20th - 31st October 2012
(extension returns 5th November 2012)

India & Bhutan
Heritage & Himalayas

What a trip! India is a country of incredible contrasts and this Conference Plus GP refresher course is designed to give you an experience of the enormous variety to be experienced in this alluring land. Our Colonial themed tour will include Mumbai, Calcutta & Darjeeling - MORE! A 4 night post course tour of the stunning Kingdom of Bhutan or a wonderful trek in the Himalayas.

EXPERIENCE OUR
SUPERB ACADEMIC
CONFERENCE WITH
HIGH QUALITY
INTERACTIVE
TEACHING PLUS
SUPERB OPTIONAL
TOUR PROGRAMME



INDIA & BHUTAN ACCOMMODATION:
4 Nights in the world famous Taj Hotel Mumbai
2 Nights in the Oberoi Grand Hotel Calcutta
3 Nights in the Woodstock Hotel Darjeeling

CONFERENCES TO COME:
Tunisia, Sicily
19th - 26th Apr 2013
Croatia
2nd - 8th Feb 2013
Cappadocia & Istanbul
May 2013
Swiss & Granada
October 2012
Paris & The Azores
October 2012



BOOK ONLINE AT: www.conferenceplus.co.uk
OR EMAIL: info@conferenceplus.co.uk
Tel: 01923 859363 Fax: 01923 469363

ABTA

Cimarron

Established and unique GP Locum Agency,
offering a professional, efficient service for all GPs.

URGENTLY REQUIRED

Primary Care and Substance
Misuse GPs required
for prison work in;
Chelmsford, Manchester,
Peterborough and Middlesex

Contact us today and see the Difference!
Phone 01206 274174
Email: enquiries@cimarron-uk.com

COOPERS
INTERNATIONAL LTD
Medical Recruitment

Successfully matching locum doctors
with surgeries since 1985

GP Locums AVAILABLE

Both Sessional

& Long Term Cover

Head Office Tel: 01223 655 411
Web: www.coopersint.co.uk
Email: enquiries@coopersint.co.uk

RELEASE YOUR SURGERY EQUITY
OR
DEVELOP YOUR NEW SURGERY
Medical Centre Developments Ltd

We are specialist developers and funders.
Talk to us about your requirements.
Contact: Christopher Holden
54 Weymouth Street, London W1G 6NU
020 7935 5042 - Email: john.dunsmuir@medicalcentres.co.uk
www.medicalcentres.co.uk



HARLEY STREET DOCTORS LTD.

Doctors required UK-wide for mobile insurance medicals,
especially in the following areas:
London, Bournemouth, Southend, Chelmsford, Reading, Southampton,
Leics., Lincs., Cambs., Herts., Dorset, Dundee & Aberdeen
Please email your CV to: peter@harleystreetgroup.co.uk
or call on 020 7224 0030

NAPC Annual Conference
and Vision Awards 2012

30-31 October – The NEC, Birmingham

A new era
for the NHS

The must-attend event for all health & social care professionals

NAPC 2012 identifies and maximises the opportunities presented by clinical commissioning and answers key questions facing NHS professionals

This is your opportunity to:

- Broaden your understanding of national policy and transformation
- Share good practice to manage long-term conditions and prevent admissions
- Be inspired by commissioning initiatives to streamline services and improve outcomes
- Hear workable solutions to manage demand and improve patient access

Book your free place now at www.napcannual.co.uk

Register
for free*
today



Organised by

Practical
Commissioning

PULSE

* Free for the first 400 NHS and local authority delegates, prices from £99 + VAT thereafter.

EDITOR'S CHOICE

A life without benefits

Patients refused disability living allowance should be offered counselling to help them focus on what they can do - not what they have lost, says Dr Stuart Berry

A friend commented recently that she had walked past a billboard saying: 'One-legged man refused disability living allowance.' She initially felt sorry for the chap - why shouldn't he be able to claim when he had been left disabled by an accident? But this was quickly followed by some thoughts about what jobs



Dr Stuart Berry: provide CBT

remained open to him.

It's great that obvious benefits cheats don't always profit from their fraudulent ways - but what about the cases that are less clear-cut?

Patients who are refused DLA should be automatically offered counselling and advice about the reasons for their rejection and how that opinion has been reached. They should be offered cognitive behavioural therapy so they can start thinking more positively about the sorts of jobs they can do, instead of focusing on what they have lost.

Rejection from DLA can

lead to patients considering suicide, as they feel they cannot ever find a job or income that will allow them to carry on. Offering a fast track into CBT or interview with an occupational therapist can prove beneficial to the patient - and their family - in the long term.

Dr Stuart Berry is a GP in Pendle, Lancashire, and communications lead for East Lancashire CCG

MORE ONLINE
Read the full article
pulsetoday.co.uk/opinion

VIDEO



LMCs enjoyed some comic relief, Scouse-style, with Dr Ivan Camphor and Dr Neville Bradley donning traditional outfits to argue the conference should return to Liverpool. Watch it and other videos from the LMC conference last week.

pulsetoday.co.uk/videos

LCP
SPOON
ADVANCE
ACTIVE

Not everything to do with milk is so black and white

Cows' milk allergy (CMA) can be a distressing condition for affected infants and their families. That's why Nutricia, with 25 years' experience of producing the Neocate amino acid range, is working with Allergy UK and Dr Adam Fox on a campaign to raise awareness of CMA amongst parents.

The campaign features:

- ✓ a website, www.cowsmilkallergy.co.uk
- ✓ a national awareness day on 7th June
- ✓ educational pieces featuring across a wide range of media (print, radio, webchat TV).

For more information on GP resources to support the diagnosis and treatment of CMA, call Nutricia on 08457 623 653.

Date of preparation: April 2012

WHAT YOU'VE BEEN SAYING

pulsetoday.co.uk/forum

GPs are beginning, at last, to see how the maths is adding up to a peach of a Copperfield article.

... on how GPs' pay may be docked over pensions action

The BMA never gets its powder wet - we will be waiting till pigs start flying.

... on GP opposition to revalidation

Faces look so lonely without their noses.

... on LMCs demanding a commissioning boycott over pensions



MAP CCGs' proposed running-cost allowance

Go online to see an interactive map showing the 212 proposed CCGs and their indicative running-cost allowance.


INTERACTIVE MAP
pulsetoday.co.uk/maps

THIS WEEK'S POLL

Should drug firms help plan and manage NHS services?

Vote at pulsetoday.co.uk/polls

Last week's poll
Will online booking ease the '8am rush'?



Turn inside for this week's Phil Peverley and Margaret McCartney columns
[page 14](#)